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HIV is known to affect the epidemiology, transmission, pathogenesis and natural history of 
HCV infection whilst studies on the effects of HCV on HIV have shown conflicting results 
and are confounded by the influence of intravenous drug use and anti-retroviral therapy. 
This study was conducted in KwaZulu-Natal Province in South Africa where HIV is 
predominantly a sexually transmitted infection. Intravenous drug use is rare in this region 
and the study population was naive to anti-retroviral therapy.  
For this study, specimens from selected sentinel sites submitted to a central laboratory for 
routine HIV testing were screened for anti-HCV IgG antibodies. HIV positive HCV-
positive patients were compared to HIV-positive HCV-negative patients in a subgroup of 
patients within this cohort in order to determine if HCV sero-prevalence was associated 
with clinical outcomes in a linked anonymous retrospective chart survey.  
The prevalence of HCV was 6.4% and that of HIV, 40.2%. There was a significantly 
higher prevalence of HCV among HIV infected patients as compared to HIV negative 
patients (13.4% vs. 1.73% respectively). HCV-HIV co-infected patients had significantly 
increased mortality (8.3 vs. 21%). A significant association was found between HCV 
serostatus and abnormal urea and creatinine levels. Hepatitis B surface antigen seropo-
sitivity was not found to be a confounding factor. 
This study has found that hepatitis C co-infection is more common in HIV positive 
individuals and is associated with an increased mortality and renal morbidity. 
 
 xv
1 CHAPTER ONE: INTRODUCTION AND LITERATURE 
REVIEW 
1.1 HIV  
HIV is a cytopathic retrovirus that targets primarily CD4+ lymphocytes. The destruction of 
CD4+  lymphocytes results in an inexorable decline in immune function, which leads to 
AIDS, a syndrome characterized by the development of unusual tumours and infections 
which are rarely seen in immune-competent individuals. The progression and natural 
history of HIV is intimately linked to the development of these opportunistic infections. 
Incidental, concomitant and opportunistic co-infections interact with HIV on an 
epidemiological, clinical, pathogenic, immunological and therapeutic level. In the absence 
of a cure for HIV, efforts are being directed at controlling and treating opportunistic 
infections, particularly where effective therapies or vaccines are available. (Braunwald et 
al., 2001). 
 
These co-infections play a particularly important role in the African continent where HIV 
and other infections are highly prevalent (Lawn, 2004). In the province of KwaZulu-Natal 
in South Africa, for example, the National Antenatal HIV and Syphilis Sero-prevalence 
Survey found that approximately 39.1 % of antenatal attendees were HIV positive in 2005 





HCV, a single stranded RNA virus that belongs to the genus Hepacivirus within the family 
Flaviviridae, was discovered in 1989 as a cause of Non-A Non-B hepatitis (Larson and 
Carithers, 2001). Yellow Fever virus, West Nile virus, Dengue virus and Hepatitis G virus 
are other examples of viruses belonging to the family Flaviviridae. The virus consists of a 
single strand of positive sense RNA of about 9500 bases, which is surrounded by a nucleo-
capsid protein and lipid envelope (Lauer and Walker, 2001). 
 
1.2.2 Pathogenesis 
HCV primarily targets the hepatocyte, although monocytes and lymphocytes may also be 
infected (Thomas, 2002). HCV interacts with Major Histocompatibility Complex (MHC) II  
molecules on antigen presenting cells which results in the activation of Th1 CD4+ T-cells. 
This leads to the release of cytokines such as TNF-α, TNF-γ and IL-2 which activate 
macrophages, Natural Killer cells and Kuppfer cells resulting in the phagocytosis and lysis 
of infected hepatocytes. Infected and uninfected hepatocytes are also targeted and lysed by 
cytotoxic CD8+ T-cells. Anti-HCV antibodies play a role by facilitating opsonisation. The 
lysis of hepatocytes results in increased transaminase levels. The destruction of 
hepatocytes is therefore immune mediated and not due to the direct effects of HCV, which 
appears to be non-cytopathic. Destruction of all infected hepatocytes by these mechanisms 
results in viral clearance. The inability to clear infected hepatocytes results in chronic 
infection (Gonzalez and Talal, 2003, Mohsen et al., 2002). This inability to clear the virus 
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is largely due to the capacity of the virus to escape from the immune system due to its 
extraordinary diversity. This diversity is generated by an extremely high viral replication 
rate and the lack of a proof-reading mechanism (Lauer and Walker, 2001). Patients who 
clear acute hepatitis C infection are not protected from re-infection and multiple bouts of 
infection have been reported (Fields et al., 2001). 
 
1.2.3 Epidemiology 
Epidemiological studies of HCV are challenging since most cases of HCV infection are 
asymptomatic and indistinguishable clinically from other causes of hepatitis (see 1.2.5.6). 
A laboratory diagnosis is therefore essential, but not always available, particularly in 
resource- limited settings. There are consequently few population-based epidemiological 
studies of HCV. Most studies are based on select high risk (e.g. intravenous drug users) or 
low risk (e.g. blood donor) populations which either overestimate or underestimate the true 
prevalence respectively (Ray Kim, 2002).  
 
HCV is endemic worldwide, with an estimated global prevalence of 3%, which represents 
170 million people. HCV is four to five times more prevalent than HIV globally (Winnock 
et al., 2004) and is the commonest chronic blood-borne infection in the United States 
(Gonzalez and Talal, 2003).  Three to four million people are infected by HCV every year 
(Madhava et al., 2002).  
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There is great variation in the geographical distribution of HCV, with the highest 
prevalence in Africa and Asia, and lower prevalence in industrialized countries (Figure 1). 
Even within developing nations, there is great variation in prevalence, ranging from 0.9% 
in India and 3.2% in China, to the highest reported prevalence in Egypt of 22%. Some of 
this variation may be explained by differences in study and reporting methods. Actual 
differences in HCV prevalence may be due to variation in risk factors in different parts of 
the world. Injection drug use is the single most important risk factor in developed regions 
of the world. Unsafe therapeutic injections and blood transfusions are important risk 
factors in developing nations where these practices occur. Occupational, peri-natal and 
sexual exposure, and tattooing, body-piercing, acupuncture and scarification are other 
modes of HCV transmission. The relative contribution of these risk factors to the 
prevalence of HCV is poorly defined, particularly in developing regions of the world (Ray 
Kim, 2002, Shepard et al., 2005).  
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Figure 1 The global prevalence of HCV (Shepard et al., 2005) 
 
Sub-Saharan Africa has the highest prevalence of HCV (5.3%) among the WHO world 
regions. Within this region there are remarkable differences in prevalence: the central 
African region has the highest prevalence (6%), and Southern and East Africa, the lowest 
(1.6%). Cameroon has the highest national prevalence of 12% and South Africa the lowest 
(0.1%) among blood donors. It is postulated that the HCV epidemic may be at different 
time points in these regions. Variations in the use of unsterile injections in medical 
procedures, screening of blood donors and scarification practices may also explain some of 
these differences. Among countries in Africa, only South Africa and Zimbabwe are known 
to consistently and routinely screen for HCV in blood donors. The risk of transmission of 
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HCV through an unsafe injection is estimated to be 6%. Africans are estimated to receive 
1.5 unsafe therapeutic injections per year. Studies have demonstrated the association 
between injections, e.g. hormonal contraceptives, and HCV seropositivity. (Madhava et al., 
2002). 
 
The prevalence of HCV may be influenced by the varying prevalence of HIV and other 
sexually transmissible infections within the continent. HIV is known to increase the mother 
to child transmission of HCV, and sexually transmitted infections may facilitate the 
heterosexual transmission of HCV. The magnitude of intravenous drug use and its 
contribution to the geographical variations in HCV prevalence is unknown (Madhava et al., 
2002). 
 
There are several unique factors within the Southern African region which may influence 
the outcome of prevalence studies: Antibody tests designed for HCV genotypes and 
subtypes common in Europe and North America may not be as sensitive and specific 
against viruses circulating in Africa. The immunology of HCV clearance may be different 
in African patients, who may clear HCV infection more readily and retain antibodies for 
longer periods. The impact of HCV is exacerbated by the concurrent HIV epidemic within 
this region. There is a clear need for well designed population based studies of the 
epidemiology of HCV within this region (Madhava et al., 2002). 
 
 6
There are likewise few representative studies investigating the prevalence of HCV in South 
Africa. The estimated prevalence in South Africa is 4.3 – 65% (average 23.5%) in  high 
risk cohorts (patients  with liver disease, patients receiving multiple blood transfusions or 
blood products, patients on dialysis and renal transplant patients (Madhava et al., 2002). 
The estimated prevalence in low-risk cohorts such as  blood donors, on the other hand, is 
as low as 0.1% (Madhava et al., 2002). Seroprevalence in the blood donor population was 
0.16, 0.34, 0.75, and 0.22% for whites, Asians, Africans, and Coloureds, respectively, in a 
study carried out in 1993 (Soni et al., 1993). A survey of blood donors in the Western Cape 
found a seropositivity of 0.41% (Tucker et al., 1997). HCV antibodies were found in 1.8% 
of healthcare workers in a large urban referral hospital in South Africa (Vardas et al., 
2002). A previous study within KwaZulu-Natal found a low prevalence of HCV of 1.7% 
and 0.9% among urban and rural blacks, respectively (Abdool Karim and Tait, 1993). The 
prevalence of HCV among HIV positive patients attending the Chris Hani Baragwanath 
Hospital in Johannesburg, was also found to be low (1%) (Lodenyo et al., 2000). In 
contrast, the prevalence of hepatitis C was found to be 11% among patients experiencing 
early hepato-toxicity in a randomized controlled trial that included nevirapine as part of the 
antiretroviral regimen (Sanne et al., 2005).  
 
There is a relationship between the prevalence of HCV and the mode of transmission. In 
regions with low prevalence, such as USA and Europe, most infections are acquired from 
injection drug use in young adults. In areas with intermediate prevalence, such as Japan 
and Italy, healthcare related procedures such as transfusions, unsafe injections and 
acupuncture predominate. In areas with a high prevalence, such as Egypt and Pakistan, 
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healthcare related procedures are the major source of transmission. Peri-natal transmission, 
which is enhanced by HIV infection, contributes to a pool of infected individuals who 
maintain a high prevalence of HCV in these regions (Ray Kim, 2002). 
 
The demographic and socio-economic characteristics of HCV positive individuals are also 
influenced by the distribution of risk factors. In the United States, for example, high risk 
drug-taking and sexual behavior and receiving blood donations before 1992 are important 
risk characteristics. In the USA, HCV prevalence is higher in men than in women and in 
non-Hispanic blacks than in non-Hispanic whites and Mexican Americans. The peak 
prevalence is in the 40-49 year age group (Armstrong et al., 2006). The demographic 
distribution in developing regions is less well studied. 
 
The epidemiology of HCV is affected by HIV and HBV co-infection. HIV, HCV and HBV 
share common risk factors and routes of transmission. The prevalence of co-infection 
varies by region and is influenced by the nature of the common risk factor. In HIV-infected 
individuals with a history of intravenous drug use, for example, the prevalence of co-
infection is over 80%. In regions where HIV is predominantly a heterosexually transmitted 
infection, the prevalence of co-infection is much lower, usually < 7%. There is a paucity of 
data on the prevalence of HIV-HCV co-infection in developing countries where the 
administration of unsafe therapeutic injections to HIV positive individuals is postulated to 
contribute to co-infection. The role of heterosexual transmission remains poorly defined. 
The prevalence of HBV-HCV co-infection is also uncertain. Most published studies are 
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based on high risk groups such as intravenous drug users. Co-infection rates in developing 
countries in particular, are unknown (Shepard et al., 2005). 
 
Assessing mortality and morbidity associated with HCV infection is difficult since most 
infections remain asymptomatic and complications such as hepatocellular carcinoma, 
cirrhosis and liver failure occur late and only in a small proportion of those infected. Once 
they do occur, however, they require intensive utilization of healthcare resources and 
contribute significantly to the reduction of disability adjusted life years (DALYs). The 
complications of HCV are similar to those of HBV infection, and available data on the 
global burden of liver disease do not distinguish between the two infections (Ray Kim, 
2002). The potential impact of HCV is more challenging to assess in developing countries 
where HCV infected individuals die from other causes such as HIV and TB, before the 
onset of the complications of HCV. More research is clearly needed to assess the impact of 
HCV on morbidity and mortality in developing countries. 
 
1.2.4 Transmission 
There are multiple routes of transmission of HCV. HCV is a blood-borne infection which 
is transmitted sexually and vertically and by iatrogenic, occupational, cultural and 
recreational activities. Unsafe transfusions and therapeutic injections and acupuncture are 
examples of iatrogenic transmission. Intravenous drug use, tattooing, scarification and ear-
piercing are examples of recreational and cultural activities that may spread HCV. HCV 
may also be transmitted by needle-stick injuries (Hughes and Mahy, 1998).  
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Parenteral person-to-person transmission from a chronically infected individual is 
postulated to be the commonest mode of spread. Intravenous drug use and blood 
transfusions have been the most important mechanisms of parenteral transmission in 
Western countries (Winnock et al., 2004). The predominant route of transmission in 
developing countries remains to be defined.  
 
Hepatitis C is 10 times more efficiently transmitted than HIV through percutaneous blood 
exposure such as needlestick injuries, where the risk of transmission is about 30/1000 
exposures, and injection drug use, where the incidence of HCV is substantially higher than 
that of HIV (Sulkowski and Thomas, 2003, Thomas, 2002, Winnock et al., 2004). In 
contrast, the sexual and vertical transmission of HCV is far less efficient than that of HIV 
(Thomas, 2002) since mucosal transmission is relatively inefficient. Unlike other 
flaviviruses, HCV is not thought to be transmitted by insect vectors (Fields et al., 2001). 
 
The risk of transmission of Hepatitis C by blood transfusion and immunoglobulin 
administration has been drastically reduced by the use of a volunteer donor system, pre-
donation risk assessment questionnaire and routine screening of blood donors for 
antibodies against HCV. This risk has been further reduced by the introduction of NAT 
testing, which identifies HCV RNA during the antibody window period, and viral 
inactivation of immunoglobulin products (Fields et al., 2001, Sulkowski and Thomas, 
2003, Winnock et al., 2004). In developed countries, transmission by intravenous drug use 
is more common than transmission by blood transfusions (Winnock et al., 2004). In 
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countries such as South Africa, where antibody and NAT testing are routinely practiced in 
the blood transfusion service, transfusion-acquired HCV is unlikely to contribute 
significantly to the prevalence of HCV (Heintges and Wands, 1997, Madhava et al., 2002). 
 
Perinatal transmission most likely occurs during labor or at the time of delivery. The risk, 
in the neonate, of chronicity of perinatally transmitted HCV infection is increased by HIV 
co-infection and is related to maternal HCV viral load. Perinatal infection is unlikely if 
HCV RNA is undetectable in the maternal circulation. HCV RNA is undetectable in 
breastmilk; however the risk of HCV transmission by breastfeeding remains undefined 
(Heintges and Wands, 1997). 
 
The rate of sexual transmission of HCV is low and is much lower than that of Hepatitis B 
and HIV. The prevalence of HCV in STI clinics is low, and the incidence of HCV in 
sexual partners of HCV carriers is low. For these reasons, HCV has not usually been 
considered a sexually transmitted infection (Bouvet, 2005). On the other hand, HCV 
seropositivity does correlate with the number of sexual partners, the presence of sexually 
transmitted infections and employment in the sex industry (Sulkowski and Thomas, 2003, 
Fields et al., 2001). These conflicting findings make it difficult to assess the extent of the 
sexual transmission of HCV infection (Hughes and Mahy, 1998). 
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The risk of sexual transmission varies geographically and is confounded by factors such as 
the use of intravenous drugs, shared use of razors and toothbrushes and condom-use. 
Sexual transmission is also influenced by the number of sexual partners and syphilis and 
HIV seropositivity. HIV co-infection is thought to enhance the sexual transmission of 
HCV (Sulkowski and Thomas, 2003, Winnock et al., 2004). The risk in homosexual and 
heterosexual relationships appears to be similar (Heintges and Wands, 1997, Wejstal, 




1.2.5.1 Acute Hepatitis 
The average incubation period is 7 weeks, but this may vary widely depending on the 
inoculum and route of transmission. Prodromal symptoms are rare. Acute hepatitis C 
infection is icteric in only 20% of patients and other symptoms occur infrequently and are 
rarely severe. Symptoms are similar to those of other forms of acute hepatitis and include 
malaise, nausea, right upper quadrant pain, dark urine and jaundice. Symptoms, when they 
do occur, last for up to 12 weeks. Complications such as fulminant hepatitis are rare. Since 
most infections are asymptomatic, and the symptoms are non-specific when they do 
develop, the diagnosis of Hepatitis C is based on laboratory markers rather than clinical 
symptoms. Biochemical markers such as elevated ALT, occur in 80% of patients with 
acute hepatitis (Fields et al., 2001, Marcellin, 1999). 
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1.2.5.2 Chronic Hepatitis 
Approximately 85% of patients with acute hepatitis develop chronic hepatitis C infection, 
where the virus persists for greater than 6 months, and usually, for life.  Chronic hepatitis 
C infection is usually asymptomatic. Two patterns of infection occur, although the 
presentation varies widely: 
Chronic Hepatitis C infection with normal ALT 
Approximately 25% patients with chronic hepatitis C infection will have normal ALT 
levels. These patients are usually asymptomatic. Patients with normal ALT levels have 
normal liver histology or histology with mild-moderate chronic hepatitis with minimal or 
absent fibrosis. Cirrhosis is rare in this group (Marcellin, 1999). 
Chronic Hepatitis C infection with elevated ALT levels 
The remaining 75% of patients with chronic HCV infection have elevated ALT levels. The 
severity of hepatitis varies widely in these patients; two histological patterns can be 
distinguished: 
Mild Chronic Hepatitis:  
These patients have a fibrosis score of ≤ 1 and an activity score of < 6 as described by 
Knodell (Knodell et al., 1981, Brunt, 2000). Patients with this form of hepatitis complain 
of mild non-specific symptoms such as fatigue, nausea, anorexia, and weight loss. Overt 
symptoms of liver disease, such as right upper quadrant pain, dark urine, pale stools, 
jaundice and pruritis may also occur (Fields et al., 2001). Fatigue is the commonest and 
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often the only symptom, and may affect the patient’s quality of life (Marcellin, 1999, 
Fields et al., 2001). 
 
Moderate and Severe Chronic Hepatitis 
These patients have marked necro-inflammatory lesions and extensive fibrosis 
corresponding to a fibrosis score of ≥ 3 and an activity score of ≥ 6. This group includes 
patients with bridging fibrosis and cirrhosis. Neither the severity of symptoms nor the level 
of ALT is consistent in predicting the severity of hepatitis, and liver biopsy remains the 
most reliable method of predicting or identifying cirrhosis. Patients, who are older, are 
immunocompromised or who consume alcohol are more likely to have severe chronic 
hepatitis (Marcellin, 1999). 
 
1.2.5.3 Cirrhosis 
Cirrhosis develops after 2 to 3 decades of Hepatitis C infection. The development of 
cirrhosis is influenced by several factors including the consumption of alcohol, co-
infection with Hepatitis B virus or HIV, and age. Cirrhosis remains silent for many years, 
until the symptoms of end-stage liver disease appear. These include marked fatigue, 
muscle wasting, fluid retention, pruritis, jaundice and bleeding tendencies. Symptoms 
related to portal hypertension (oesophageal varices, splenomegaly, ascites) and liver 
failure/hepatic encephalopathy (confusion, coma, asterixis, fetor hepaticus, and 
construction apraxia) represent the late stage of the disease (Braunwald et al., 2001). 
Patients with chronic liver disease die from portal hypertension, liver failure or  
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hepatocellular carcinoma, although a proportion die of other causes unrelated to liver 
disease (Marcellin, 1999). 
 
1.2.5.4 Hepatocellular Carcinoma 
Hepatocellular carcinoma is the most serious outcome of cirrhosis in patients with 
Hepatitis C infection. Chronic infection with Hepatitis C virus results in chronic 
inflammation, necrosis, regeneration and cirrhosis, which contribute to oncogenesis. 
Hepatitis C virus is an unusual oncogenic virus in that it does not possess DNA in its 
genome or its replication cycle, and therefore cannot integrate into the human genome.  Its 
oncogenic potential is thought to arise from the continuous insult on hepatocytes and the 
resulting regeneration and inflammation. The HCV core protein, NS5A and NS3 proteins 
are also thought to play a role in oncogenesis (Fields et al., 2001). Hepatocellular 
carcinoma may remain asymptomatic for many years.  
 
1.2.5.5 Extrahepatic Manifestations 
The liver is not the only organ affected by hepatitis C infection. A range of extra-hepatic 
manifestations are described in chronic hepatitis C infection. There is a strong association 
between HCV infection and mixed essential cryoglobulinemia, memranoproliferative 
glomerulonephritis, sicca syndrome and polyarteritis nodosa. Other manifestations such as 
porphyria cutanea tarda, low grade lymphoma, automimmune thyroiditis, lichen planus, 
aplastic anaemia, thrombocytopenia, erythema nodosum, diabetes mellitus and neuropathy 
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are less well documented and further research is needed (Marcellin, 1999). Many of these 
conditions are thought to arise from an autoimmune mechanism (Fields et al., 2001, Manns 
and Rambusch, 1999, Marcellin, 1999).  
 
Mixed cryoglobulinemia is the most well described extrahepatic manifestation of Hepatitis 
C infection. Cryoglobulins consist of immune complexes of HCV and its antibody, 
rheumatoid factor, immunoglobulins and complement, which usually cause no symptoms, 
although rarely, arthralgia, Raynaud’s disease, vasculitis, glomerulonephritis and purpura 
result (Fields et al., 2001).  
 
1.2.5.6 Asymptomatic Infection 
Most HCV infections are asymptomatic. The prodrome, acute infection and chronic 
infection are usually clinically silent. The symptoms of acute and chronic HCV infection, 
when they do occur, are nonspecific and indistinguishable from other causes of hepatitis 
such as HAV, HBV, alcohol and toxins. Consequently, most HCV infections are diagnosed 
not by symptoms, but fortuitously by laboratory tests. Many patients therefore remain 
undiagnosed, untreated and infectious, particularly in resource poor settings where 
screening for HCV is not readily available. The clinically silent nature of HCV infections 
necessitates the use of laboratory tests, rather than clinical case definitions, in 
epidemiological investigations (Marcellin, 1999, Fields et al., 2001). 
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1.2.6 Natural History 
The natural history and disease spectrum of Hepatitis C infection are variable and 
incompletely defined. The asymptomatic course, slow progression and effects of treatment 
and multiple cofactors contribute to the complexity of studying the natural history of HCV. 
The onset of acute infection and transition from acute to chronic infection are most often 
covert; overt symptoms may occur only in the final stages of infection, and many patients 
die from other causes before this. The critical events in the natural history of HCV 
infection are therefore inconspicuous and the natural history difficult to study (Alberti et 
al., 1999, Seeff, 2002). The natural history of HCV is summarized in Figure 2. 
 
A few patients who are repeatedly exposed to HCV develop a self-limiting sub-clinical 
HCV infection with no detectable anti-HCV. Most patients who are exposed to HCV 
develop acute hepatitis C and detectable anti-HCV antibodies. Most patients with acute 
hepatitis C progress to chronicity.  Only 10-15% of patients resolve the infection 
completely, although more recent studies in non-transfusion related HCV infection indicate 
that the clearance rate may be as high as 50%, particularly with low dose inoculums. It is 
not known why some patients clear the infection while others fail to do so, but a vigorous 
T-cell immune response is likely to play a role. Clearance may occur early i.e. less than 6 
months post-infection, or late (1-4 years later). Determining the rate of progression to 
chronicity is difficult because most acute infections are asymptomatic and remain 
undiagnosed.  The progression to chronicity is influenced by the route of infection, dose of 
the inoculum, immunosuppression, HIV co-infection, and host immunogenetic factors. 
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Younger, female, non-black immunocompetent patients are less likely to develop chronic 
infection (Alberti et al., 1999, Hoofnagle, 2002, Thomas et al., 2000). 
 
The chronicity rate of HCV infection is lower in younger patients, which contrasts with 
HBV infection where infection early in life is likely to become chronic. The chronicity rate 
of HCV in patients who are less than 20 years of age is estimated to be 30%; the rate in 
those older than 20 is 76%. The chronicity rate is lower in women, particularly younger 
women, although this is controversial. Similarly, black patients are less likely to clear HCV 
infection than Caucasians and Hispanics. Black men in particular have the highest rates of 
chronicity, approaching 98% (Hoofnagle, 2002, Thomas et al., 2000).  
 
Chronic infection may develop with or without biochemical abnormalities, inflammation, 
fibrosis or cirrhosis. Viremia may be persistent or intermittent. A patient with chronic 
hepatitis will rarely clear HCV spontaneously. Spontaneous clearance occurs mainly with 
end-stage liver disease and hepatocellular carcinoma. Up to 15% of patients develop a 
carrier state with normal ALTs. Histological progression is rare in those with normal 
ALTs. A large proportion of patients with chronic HCV infection have a mild form of 
hepatitis, which remains stable for many years and rarely progresses. Approximately 20% 
of patients with abnormal ALT levels develop cirrhosis after 20 years of infection. This 
includes 5-10% of patients who develop end-stage liver disease, 1% who develop 
hepatocellular carcinoma and 4-8% who die of liver related causes. The risk of 
decompensation and cancer increases if the patient has cirrhosis: Up to 20% of patients 
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with cirrhosis decompensate within 5 years, 10 % develop hepatocellular carcinoma and 
9% die from liver related causes (Alberti et al., 1999). 
 
Several factors influence the natural history of hepatitis C infection, including the age of 
the patient when infected, gender, race, alcohol consumption (>50g per day), HBV or HIV 
co-infection , CD4+ cell count (<200cells/ml), the presence of metabolic liver disease, use 
of antiviral treatment and host genetics (MHC class II alleles). The influence of viral 
factors such as HCV viral load, quasi-species diversity and HCV genotype on disease 
progression is contentious (Alberti et al., 1999, Seeff, 2002, Massard et al., 2006, Thomas 
et al., 2000). 
 
The age at which an individual is initially infected is an important determinant of disease 
progression. Individuals who are younger (< 40 years) at the time of infection have slower 
disease progression.  It is not known, however, if the rate of disease progression increases 
with increasing age. Males progress 10 times more rapidly to cirrhosis than females, an 
effect probably related to the “protective” effects of estrogen. The rate of progression to 
cirrhosis is lower in African Americans than Caucasians (Seeff, 2002, Massard et al., 2006, 
Thomas et al., 2000). 
 
Disease progression may also be influenced by the presence of increased hepatic iron 
stores, non-alcoholic steato-hepatitis (NASH), obesity, type II diabetes and co-infections. 
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HIV and HBV infection have a profound influence on HCV disease progression due to 
their immunosuppressive and synergistic pathogenic effects, respectively. Concomitant 
infection with schistosomiasis is thought to accelerate liver fibrosis by impairing the 
immune response (Seeff, 2002, Massard et al., 2006). The effect on disease progression of 
alcohol intake of > 50 g per day is beyond dispute. The effect of lower quantities of alcohol 
is less clear. The effects of cigarette smoking may influence the development of 
hepatocellular carcinoma, but this remains controversial. The effect of environmental 
factors such as diet and toxins remain speculative (Seeff, 2002, Massard et al., 2006, 
Thomas et al., 2000). 
 
Patients may be classified as slow or non- progressors (cirrhosis > 50 years), intermediate 
progressors (cirrhosis within 20 – 50 years) and rapid progressors (cirrhosis within 20 
years). The subgroup classification correlates with mean ALT and histological activity 
grade on the first liver biopsy. Patients with normal ALTs have less fibrosis and are less 







Figure 2 Spectrum of Natural History of Hepatitis C infection. (Adapted from 
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1.2.7 Diagnosis  
Serological and molecular assays are available for the diagnosis of hepatitis C infection. A 
reliable culture system is not available for diagnostic purposes. Handling, transport and 
storing of specimens is of critical importance to the quality of laboratory results (Erensoy, 
2001). 
 
1.2.7.1 Serological Course of Acute Hepatitis 
The course of acute resolving hepatitis C infection is illustrated in Figure 3. HCV RNA, 
detectable in serum 1-2 weeks after infection, rises rapidly and peaks just before the onset 
of symptoms. Increased ALT levels, which may be up to 10 times the normal, represent 
hepatic injury and also peak at the time of onset of symptoms. Symptoms, which include 
jaundice, occur 3-12 weeks after infection in about one third of patients. In acute resolving 
HCV infection, symptoms disappear, ALT levels return to normal and HCV RNA 
disappears from the bloodstream. Anti-HCV antibodies appear at the time of onset of 
symptoms and usually persist for life, except in a proportion of patients who lose their 






Figure 3 The course of acute (A) and chronic (B) HCV infection (Fields et al., 2001). 







1.2.7.2 Serological Course of Chronic Hepatitis  
The early phase of chronic HCV infection is similar to that of the acute infection (Figure 
3). HCV RNA persists for at least 6 months in the case of chronic infection. Patients who 
develop chronic infection are less likely to have symptoms during the acute phase. Anti-
HCV antibody levels are higher and more likely to persist with chronic infection. Patients 
who evolve from acute to chronic infection have a “stuttering” pattern of infection in 
which HCV RNA levels fluctuate and may temporarily be undetectable, and ALT levels 
are transiently normal. A normal ALT and negative HCV RNA PCR therefore does not 
necessarily equate to resolution of infection. HCV RNA levels stabilize once chronic 
infection has been established and spontaneous resolution is unlikely after 6 months of 
infection (Hoofnagle, 2002). 
 
1.2.7.3 Serology 
Testing for antibodies to HCV is the initial laboratory screening method for diagnosing 
past and current HCV infection. Enzyme immunoassays (EIAs) are commercially available 
in high-through-put formats, and play a key role in diagnostic laboratories and blood-
banks. Three generations of enzyme immunoassays have been developed to detect 
antibodies against epitopes of the polyprotein encoded by the hepatitis C genome. First 
generation EIAs were developed to detect antibodies against the c100-3 nonstructural 
protein (NS4). This assay had low specificity and sensitivity (~80%) and yielded a high 
number of false positives, especially when used in low risk populations e.g. blood donors. 
Second generation EIAs incorporated the c33c non-structural (NS3) and c22-3 core 
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structural proteins which significantly enhanced the sensitivity and specificity of the assay. 
The second generation assays are significantly more sensitive than the first, and detect 10-
20% more infections and reduces the window period by up to 90 days. Third generation 
EIAs added the NS5 antigen, and reconfigured the core and NS3 antigens, which further 
improved the sensitivity and specificity of the assay (Richter, 2002, Erensoy, 2001).  
 
1.2.7.4 RIBA 
A supplemental or confirmatory strip immuno-assay, the Recombinant Immunoblot Assay 
or RIBA was developed to distinguish true and false positive EIA results by identifying 
antibodies to individual antigens in the EIA. The RIBA is an analytical serological assay 
and is analogous to the Western Blot for HIV. The RIBA contains the EIA antigens, 
human superoxide dismustase (hSOD) and an IgG control band. hSOD, which is used to 
fuse the recombinant proteins in third generation EIAs, is included in the RIBA strip to 
detect non-specific antibodies. A RIBA is considered positive if there are reactions against 
at least two antigens on the strip, with intensity greater than the IgG control, and no 
reactivity against hSOD. Reactions against only one antigen, or reactions against more than 
one antigen and the hSOD are considered indeterminate. The use of synthetic antigens in 
third generation RIBA has greatly reduced the number of indeterminate RIBAs (Richter, 
2002, Erensoy, 2001). 
 
 25
1.2.7.5 Limitations of Serological Methods 
Serological assays are not reliable in diagnosing acute infection since antibodies are 
detectable in only 50% of cases at this time. Antibodies are more consistently measured 3 
months after the infection i.e. beyond the serological “window period”. Serological assays 
cannot distinguish between acute and chronic infection. IgM, for example, cannot be used 
as a marker of acute infection since it is detectable in up to 50% of chronic infections as 
well. Patients who are immunocompromised, undergoing dialysis, or who have 
cryoglobulinemia, may yield false negative results on EIA. In these cases, sensitive 
molecular detection techniques are essential for diagnosis (Richter, 2002). False positives 
may also occur due to non-specific binding of serum immunoglobulins to contaminants in 
the antigen preparations or to coating or blocking reagents (Erensoy, 2001). Confirmatory 
tests such as RIBA are essential in such cases. 
 
The RIBA is more specific, but less sensitive than EIAs and may therefore yield 
indeterminate or even negative results. This may occur, for example, during early sero-
conversion, where antibody levels are yet to rise to detectable levels, or in organ transplant 
patients, where antibody production is blunted. RIBA is particularly ineffective in 
resolving weakly positive EIAs. In this case, a more sensitive molecular method, such as 
PCR, is required. Alternatively, the serological assay may be repeated at a later date, when 
antibody titres have increased (Erensoy, 2001, Richter, 2002). 
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Confirmation of the presence of anti-HCV antibodies does not imply active disease or 
recovery (Erensoy, 2001). Patients may remain HCV seropositive for life even after the 
infection has cleared. On the other hand, patients with active disease may be anti-HCV 
antibody positive. 
 
1.2.7.6 Antigen detection 
A commercially available ELISA kit is available which detects HCV core antigen. The 
assay employs an immune-complex dissociation step which vastly improves its sensitivity, 
but the lower level of detection is still higher than that of molecular methods (Richter, 
2002). The assay has not been validated for routine clinical use (Erensoy, 2001). 
 
1.2.7.7 Molecular Diagnosis 
HCV RNA can be detected as soon as one week post-infection and is regarded as the gold 
standard in defining active HCV infection. A single negative RNA test, however, does not 
exclude the possibility of active infection, since RNA levels fluctuate and may transiently 
drop to below-detectable limits. HCV RNA may be detected using commercially available 
kits or in-house “home-brew” methods. A target amplification method such as reverse 
transcriptase PCR (RT-PCR) or transcription mediated amplification (TMA) or a signal 




RT-PCR uses primers corresponding to the highly conserved 5’ untranslated region (5’ 
UTR) and a HCV-specific oligonucleotide probe. Primer design is of particular 
significance because of the genetic heterogeneity of the HCV genome. A commercially 
available semi-automated RT-PCR kit is available (Roche AMPLICOR®, Roche 
Diagnostics, Branchburg, NJ, USA). TMA employs the enzymatic activities of a T7 RNA 
polymerase promoter, reverse transcriptase and RNase H in an isothermal reaction that 
results in detectable copies of template. The bDNA method uses solid phase 
oligonucleotide capture probes, secondary branch probes and an enzyme linked tertiary 
probes, which results in an amplified chemiluminescent signal, which is proportional to the 
amount of input RNA (Richter, 2002, Erensoy, 2001). 
 
Carry-over amplicon contamination and PCR inhibitors in the sample may cause false 
positives and negatives, respectively, and are a major drawback of PCR. Sample collection, 
transport and storage affect the yield of RNA and hence the sensitivity of PCR (Damen et 
al., 1998, Halfon et al., 1996, Jose et al., 2003, Wang et al., 1992).  Full automation, 
availability of quality control panels and standardized commercial kits, and advances such 
as real time PCR and microchip technology have nevertheless placed molecular techniques 
in the forefront of HCV diagnosis (Erensoy, 2001). 
 
1.2.8 Treatment 
Pegylated interferon α and ribavirin have antiviral and immunomodulatory effects and are 
currently the treatment of choice for HCV infection. HCV, unlike HIV, does not integrate 
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into the host genome, and eradication by antiviral therapy is possible. However, a 
virological response i.e. undetectable HCV RNA 6 months following therapy, is achieved 
in only 56% of patients. Liver transplantation is a consideration in decompensated liver 
disease due to chronic HCV infection.  
 
1.3 Similarities and Differences between HIV and HCV 
Like HIV, HCV is a blood-borne enveloped RNA virus characterised by high viral 
replication, remarkable viral diversity, an acute infection that is frequently undiagnosed, 
the ability to escape the immune system, persistent viraemia, long periods of clinical 
latency, multiple routes of transmission and lack of an effective cure or vaccine.  
 
HIV maintains its persistence by integrating its genome into host DNA. HCV on the other 
hand is sustained by ongoing replication. HCV can be cleared and become undetectable in 
the bloodstream. In contrast, HIV never resolves and remains in the bloodstream for the 
life of the individual (Sulkowski and Thomas, 2003). HIV and HCV share common risk 
factors and routes of transmission (Gonzalez and Talal, 2003). 
 
1.4 Co-infection (Figure 4) 
HCV is a common infection in HIV infected patients and represents a complex public 
health and clinical challenge, complicated by immune suppression, drug interactions and 
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toxicities and paucity of data (Sulkowski and Thomas, 2003, Thomas, 2002). The long 
term effects of HCV-HIV co-infection are only now becoming more apparent due to the 
improved survival of HIV positive patients with the use of Highly Active Antiretroviral 
Therapy (HAART) (Winnock et al., 2004). Co-infection may have an impact on the 
epidemiology, transmission, pathogenesis, clinical features, natural history and 
management of both HCV and HIV infection. Liver disease due to HCV infection is now 
one of the leading causes of morbidity and mortality in HIV-infected patients in the United 
States (Falusi et al., 2003, Fuster and Clotet, 2003, Khalili and Behm, 2002, Mohsen et al., 
2002, Rockstroh and Spengler, 2004, Thomas, 2002). In developed countries, 
approximately 50% of mortality in HIV infected patients is due to HBV-, HCV- or 
HAART-related liver disease (Sherman, 2004). 
 
HCV and HIV have common routes of transmission. The prevalence of co-infection 
depends on the common risk factor and route of transmission (Sherman, 2004, Sulkowski 
and Thomas, 2003, Thomas, 2002, Winnock et al., 2004). Data from several studies in 
developed countries indicate that in HIV patients who have a history of intravenous drug 
use, 50% - 95% are co-infected by HCV. Similarly, 4% - 15% of HIV positive 
homosexuals, 14.3% of heterosexuals and 60 – 90 % of hemophiliacs are co-infected 
(Bonacini and Puoti, 2000, Dieterich, 2004, Fuster and Clotet, 2003, Gonzalez and Talal, 
2003, Khalili and Behm, 2002, Maier and Wu, 2002, Rockstroh and Spengler, 2004, 
Sulkowski and Thomas, 2003, Thomas, 2002). The overall prevalence of HCV infection in 
HIV infected individuals in the United States is approximately 25-30% (Khalili and Behm, 
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2002, Rockstroh and Spengler, 2004, Sulkowski and Thomas, 2003, Thomas, 2002). Data 
on the epidemiology of co-infection in developing countries is lacking. 
 
The complex interaction between HIV and HCV is shown in Figure 4 and discussed in 














Figure 4 Complex interaction between HCV and HIV 
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1.4.1 Effect of HIV on HCV 
1.4.1.1 Transmission 
It is postulated that horizontal and vertical transmission of HCV is enhanced in co-infected 
patients due to higher HCV viral loads (Sulkowski and Thomas, 2003). HIV infection 
increases the peri-natal transmission of HCV two to three fold (Mohsen et al., 2002, 
Sherman, 2004, Thomas, 2002, Winnock et al., 2004). Peri-natal transmission is enhanced 
with low CD4+ cell count, high maternal HCV viral load, vaginal delivery and infant HIV 
infection, and decreased by the use of HAART and delivery by caesarean section 
(Rockstroh and Spengler, 2004, Sulkowski and Thomas, 2003).  The effect of HIV on 
sexual transmission of HCV remains controversial. Studies on sexual transmission are 
potentially confounded by other risk factors such as intravenous drug use. The prevalence 
of anti-HCV antibodies in partners of HCV carriers ranges from 2.6 to 7.1%, which is 
increased in co-infected individuals to 9.1%. HIV is therefore thought to enhance the 
sexual transmission of HCV (Bonacini and Puoti, 2000, Gonzalez and Talal, 2003, 
Dieterich, 2004, Khalili and Behm, 2002, Maier and Wu, 2002, Mohsen et al., 2002, 
Winnock et al., 2004), although this has been disputed (Thomas, 2002). Further studies are 
needed to clarify the role of HIV on HCV transmission, particularly in Sub-Saharan Africa, 
where the prevalence of both infections is among the highest in the world (Anonymous, 





HIV may have a direct cytopathic effect on hepatocytes or induce apoptosis by an 
“innocent bystander” effect. HIV may facilitate HCV infection of extra-hepatic cells. 
These mechanisms may exacerbate liver damage in HCV infection and lead to higher HCV 
viral loads (Rockstroh and Spengler, 2004). 
 
Co-infected patients have higher serum and liver HCV RNA levels than patients who are 
infected with HCV alone (Sherman, 2004, Thomas, 2002). HCV RNA levels increase by 
approximately 0.5 to 1 log following HIV sero-conversion (Bonacini and Puoti, 2000, 
Dieterich, 2004, Khalili and Behm, 2002, Rockstroh and Spengler, 2004) and coinfected 
patients have on average a ten-fold higher HCV viral load than mono-infected patients 
(Winnock et al., 2004). This may reflect increased viral replication due to immuno-
suppression. This is suggested by the observation that HCV viral load is inversely related 
to CD4+ cell counts, although this effect has not been consistently demonstrated (Bonacini 
and Puoti, 2000, Gonzalez and Talal, 2003, Maier and Wu, 2002, Sherman, 2004, Winnock 
et al., 2004, Khalili and Behm, 2002).  It has alternatively been postulated that HIV 
facilitates HCV infection of extrahepatic cells, leading to increased viral production and 
higher HCV viral loads (Rockstroh and Spengler, 2004). Increased HCV levels may have 
an impact on response to anti-HCV therapy (Sherman, 2004). 
 
Spontaneous clearance of acute HCV infection occurs only in 5 to 10% of co-infected 
patients compared to 15 to 30% of HCV mono-infected patients, possibly due to impaired 
 34
cellular immune response to HCV due to HIV infection (Sulkowski and Thomas, 2003, 
Thomas, 2002). Co-infected patients, especially those with low CD4+ cell counts, are 
therefore less able to spontaneously clear HCV infection and more likely to develop 
chronic infection, (Fuster and Clotet, 2003, Gonzalez and Talal, 2003, Sherman, 2004, 
Thomas, 2002, Winnock et al., 2004), although this has been disputed(Dieterich, 2004). 
 
Clearance and containment of HCV infection is mediated by cytotoxic CD8+  T 
lymphocytes (CTLs). CTLs are supported by cytokines released by CD4+ T cells. The 
decrease in CD4+ T cells in HIV infection leads to diminished support for CTLs and hence 
failure to clear acute HCV infection, or to control chronic HCV infection (Rockstroh and 
Spengler, 2004). The use of HAART restores CD4+ and hence CD8+ T-cell functions. The 
subsequent CTL-mediated destruction of hepatocytes leads to a flare in hepatitis. Immune 
restoration, however, rarely leads to clearance of HCV or reduction of HCV replication 
(Rockstroh and Spengler, 2004). 
 
1.4.1.3 Clinical and Histological features 
Patients with CD4+ cell counts of less than 0.4 x109 cells/l have less piecemeal necrosis 
and portal inflammation, which is in keeping with the immune-mediated basis of HCV 
induced liver disease. Some studies have found no difference in the rate of fibrosis and 
cirrhosis between HCV mono-infected and co-infected patients, whereas others have found 
a difference. The conflicting findings may relate to the different CD4+ cell counts in the 
cohorts (Bonacini and Puoti, 2000).  
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Some of the extrahepatic manifestations of HCV infection such as aphthous ulceration, 
immune thrombocytopenic purpura and sialoadenitis occur in HIV infection as well 
(Gonzalez and Talal, 2003). 
 
1.4.1.4 Disease Progression 
Studying the natural history in co-infected patients is difficult because of the indolent 
course of HCV infection and the potential confounding effects of alcohol consumption, 
antiretroviral therapy and Hepatitis B infection (Bonacini and Puoti, 2000, Graham et al., 
2001). Disease progression is potentially influenced by race, gender, genotype of HCV and 
risk factors in the population being studied (Graham et al., 2001). HIV, nevertheless, does 
appear to affect every stage of the natural history of HCV infection (Winnock et al., 2004, 
Thomas, 2002, Graham et al., 2001), resulting in higher viral loads, increased activity on 
liver histology, more rapid fibrosis and cirrhosis and an increased risk of liver failure and 
hepatocellular carcinoma (Sulkowski and Thomas, 2003, Thomas, 2002, Graham et al., 
2001). Patients with co-infection are therefore more likely to die from advanced liver 
disease than mono-infected patients (Rockstroh and Spengler, 2004). 
 
This acceleration in the course of HCV infection, due to HIV-induced immunosuppression, 
occurs particularly when there is an AIDS defining condition or if the CD4+ cell count 
drops to below 100 cells/µl (Khalili and Behm, 2002, Mohsen et al., 2002, Rockstroh and 
Spengler, 2004, Graham et al., 2001). Lower CD4+ cell counts are associated with 
increased fibrosis, cirrhosis and hepatic decompensation. It is postulated that a decline in 
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CD4+ cell counts leads to a shift in cytokine response from a Th1 to a Th2 pattern. Th2 
cytokine production has been shown to be linked to increased fibrogenesis in mice 
(Bonacini and Puoti, 2000, Gonzalez and Talal, 2003). The increased mortality and 
morbidity associated with liver disease in HIV-infected patients has nevertheless been 
noted  irrespective of CD4+ cell counts (Monga et al., 2001). 
 
The synergistic effect of HIV-HCV co-infection results in more rapid progression of 
fibrosis and cirrhosis and an increased likelihood of hepatic failure and death (Fuster and 
Clotet, 2003, Gonzalez and Talal, 2003, Khalili and Behm, 2002, Maier and Wu, 2002, 
Sherman, 2004, Graham et al., 2001). The rate of fibrosis is reported to be increased at 
least two-fold in co-infected patients particularly when the CD4+ cell count is below 200 
cells/mm3 (Thomas, 2002). Co-infected patients develop cirrhosis on average 7 years after 
infection, as compared to 23 - 30 years in HCV mono-infected patients (Maier and Wu, 
2002, Winnock et al., 2004). The relative risk of developing cirrhosis or decompensated 
liver disease in co-infected patients is approximately 2.9 (Mohsen et al., 2002, Graham et 
al., 2001) which is comparable to the effect of alcohol on the progression of chronic liver 
disease (Graham et al., 2001). 
 
HIV infection is a risk factor for the development of hepatocellular carcinoma in HCV-
infected patients (Gonzalez and Talal, 2003). Co-infected patients develop hepatocellular 
carcinoma earlier than HCV mono-infected patients (Mohsen et al., 2002, Rockstroh and 
Spengler, 2004).  
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HCV-related liver disease is a leading cause of death in HIV/AIDS clinics in North 
America (Dieterich, 2004) and an important cause of hospitalization in HIV infected 
patients (Dieterich, 2004, Gonzalez and Talal, 2003, Maier and Wu, 2002, Mohsen et al., 
2002, Sulkowski and Thomas, 2003). Between 12 to 45 % of deaths in HIV infected 
patients are due to liver disease (Rockstroh and Spengler, 2004).The effect of co-infection 
on mortality, however, remains controversial and reports are inconsistent with regard to the 
effect of HCV infection on survival in the HIV positive patient (Khalili and Behm, 2002). 
 
Further studies are therefore essential to determine the effect of co-infection on survival, 
particularly in Sub-Saharan Africa, where the prevalence of both viruses has reached 
alarming proportions (Anonymous, 2006, Madhava et al., 2002). 
 
1.4.1.5 Diagnosis and Monitoring 
HIV positive patients, particularly those with low CD4+ cell counts, may have falsely 
negative HCV ELISAs (i.e. detectable HCV RNA and negative ELISA) (Sherman, 2004, 
Sulkowski and Thomas, 2003). HCV ELISAs can result in 4 -6 % false negatives in HIV 
co-infected patients (Sherman, 2004, Thomas, 2002), due to impaired antibody production 
(Maier and Wu, 2002, Mohsen et al., 2002, Thomas, 2002) or loss of antibodies due to 
immunosuppression in advanced HIV infection (Rockstroh and Spengler, 2004). 
Antibodies may become detectable following HAART, presumably due to immune 
restoration (Bonacini and Puoti, 2000, Thomas, 2002). HIV infection can also lead to false 
positive ELISA results due to hypergammaglobulinaemia associated with 
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immunosuppression (Khalili and Behm, 2002, Sherman, 2004). There may also be an 
increased number of indeterminate RIBA in the co-infected patient (Khalili and Behm, 
2002, Thomas, 2002), due to the differential loss of anti-HCV antibodies following 
immunosuppression (Sherman, 2004). Other studies, however, have shown no difference in 
the sensitivity of HCV ELISAs in HIV positive and negative patients (Gonzalez and Talal, 
2003). 
 
1.4.2 Effect of HCV on HIV 
1.4.2.1 Transmission 
HIV vertical transmission may be increased if the mother is HCV co-infected (Bonacini 
and Puoti, 2000, Khalili and Behm, 2002, Mohsen et al., 2002, Winnock et al., 2004). The 
effect of HCV on the sexual transmission of HIV remains controversial (Sherman, 2004). 
 
1.4.2.2 Pathogenesis 
The mechanisms of direct viral interactions between HIV and HCV remain an area of 
unexplored research. Although the primary site of HCV infection is the liver, HCV is also 
known to infect lymphocytes and monocytes. HCV may lead to immune mediated 




1.4.2.3 Disease Progression 
The effect of HCV co-infection on the prognosis and progression of HIV infection remains 
controversial (Rockstroh and Spengler, 2004, Sherman, 2004, Sulkowski and Thomas, 
2003, Monga et al., 2001). Some studies have indicated no difference (Staples et al., 1999) 
while others have shown accelerated progression to an AIDS defining condition and death 
in co-infected patients (Bonacini and Puoti, 2000, Dieterich, 2004, Fuster and Clotet, 2003, 
Gonzalez and Talal, 2003, Khalili and Behm, 2002, Maier and Wu, 2002, Mohsen et al., 
2002). The Swiss Cohort study, for example, showed increased risk of progression to 
AIDS and death and diminished recovery of CD4+ cells following HAART in co-infected 
patients (Greub et al., 2000). HCV therefore seems to blunt immune recovery (Sulkowski 
and Thomas, 2003, Thomas, 2002). However, this effect is true only in short term follow-
up. On extended follow-up, there seems to be no difference in mortality between HIV 
mono-infected and HIV-HCV co-infected patients, particularly if the patients are on 
HAART (Rockstroh, 2006, Rockstroh et al., 2005).  
 
Initiation of HAART is often deferred or delayed in co-infection due to the complexities of 
managing co-infected patients (Sulkowski and Thomas, 2003, Thomas, 2002, Rockstroh 
and Spengler, 2004). Differences in the level of compliance to HAART (Sherman, 2004) 
and other confounding factors, such as intravenous drug use (Thomas, 2002) may also 
explain the difference in studies comparing outcomes in mono-infected and co-infected 
patients. Studies carried out on ARV-naïve patients in areas where intravenous drug use is 
uncommon, are therefore essential. 
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1.4.3 Survival and Mortality in Co-infected Patients 
Co-infected patients have been shown to have reduced survival and/or increased HIV 
disease progression in some studies (Anderson et al., 2004, Braitstein et al., 2005, Greub et 
al., 2000, Rosenthal et al., 2003, Monga et al., 2001) but not in others (Sulkowski et al., 
2002, Cacoub et al., 2001, Rancinan et al., 2002, Staples et al., 1999, Tedaldi et al., 2003, 
Bonacini et al., 2004). Several factors may explain the differences in study outcomes. 
Differences in study design, cohort selection and length of follow-up may be important 
factors (Anderson et al., 2004, Greub et al., 2000, Rancinan et al., 2002, Staples et al., 
1999). Differing levels of adherence to HAART, the use of intravenous drugs, hepatotoxic 
medication and alcohol and co-infections such as hepatitis B may also be important 
confounders (Braitstein et al., 2005, Greub et al., 2000, Rosenthal et al., 2003, Salmon-
Ceron et al., 2005, Staples et al., 1999, Tedaldi et al., 2003, Bica et al., 2001, Monga et al., 
2001).  
 
Increased mortality may be due to AIDS-related causes (Braitstein et al., 2005), HAART-
associated hepatotoxicity and immune-reconstitution (Anderson et al., 2004, Rosenthal et 
al., 2003, Graham et al., 2001), limited initiation or tolerance of HAART (Braitstein et al., 
2005) or liver-related causes such as cirrhosis, liver failure, end-stage liver disease and 
hepatocellular carcinoma (Cacoub et al., 2001, Greub et al., 2000, Rosenthal et al., 2003, 
Monga et al., 2001). The increased mortality may also be due to the association of HCV 
infection with intravenous drug use (Greub et al., 2000). 
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It is postulated that hepatotoxicity associated with HAART has contributed to the increase 
in liver-related mortality. HCV infection is a risk factor for HAART-related hepatotoxicity 
(Bica et al., 2001) and conversely, HAART exacerbates HCV-related liver disease 
(Rosenthal et al., 2003). Many studies in the pre-HAART era have therefore not 
demonstrated increased mortality. On the other hand, immune restoration due to effective 
HAART has been shown to reduce liver-related mortality in HIV-HCV co-infection 
(Sherman, 2004) and to lessen the difference in survival between mono and co-infected 
patients (Tedaldi et al., 2003, Bonacini et al., 2004). It has therefore been suggested that 
the control of HIV using HAART, and maintenance of CD4+cell counts above 200 x 106  
cells/l is the first priority in co-infected patients (Bonacini et al., 2004). Co-infected 
patients nevertheless do not always benefit fully from the improved survival associated 
with HAART since they are less likely to initiate and/or tolerate antiretroviral medication 
(Anderson et al., 2004, Braitstein et al., 2005, Rancinan et al., 2002). Furthermore, HCV 
infection in itself blunts HAART-associated CD4+ cell recovery, possibly due to the direct 
pathogenic effect of HCV on lymphocytes (Greub et al., 2000, Rossi et al., 2002) although 
not all studies have shown this effect (Anderson et al., 2004, Sulkowski et al., 2002).  
 
End-stage liver disease, mainly due to HCV infection, is an important cause of (non-AIDS) 
deaths in HIV-infected patients in developed countries (Rosenthal et al., 2003, Salmon-
Ceron et al., 2005, Bonacini et al., 2004, Bica et al., 2001, Dieterich, 2004, Graham et al., 
2001). Up to 45% of deaths in HIV-infected patients are due to liver disease (Rockstroh 
and Spengler, 2004), which may manifest as cirrhosis, ascites, variceal bleeding or 
encephalopathy (Monga et al., 2001). HIV infection accelerates the course of HCV 
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infection resulting in an increase in the risk of end-stage liver disease and death (Sulkowski 
and Thomas, 2003, Thomas, 2002, Rockstroh and Spengler, 2004, Fuster and Clotet, 2003, 
Gonzalez and Talal, 2003, Khalili and Behm, 2002, Maier and Wu, 2002, Sherman, 2004, 
Mohsen et al., 2002, Monga et al., 2001). This partly explains the high number of liver-
related deaths in co-infected patients.  
 
Results from studies on the effect of co-infection on survival have been inconsistent 
(Khalili and Behm, 2002), due to differences in study design (Anderson et al., 2004, Greub 
et al., 2000, Rancinan et al., 2002, Staples et al., 1999) and the effect of multiple 
confounding factors such as antiretroviral therapy (see 1.4.4.5) and intravenous drug use 
(Braitstein et al., 2005, Greub et al., 2000, Rosenthal et al., 2003, Salmon-Ceron et al., 
2005, Staples et al., 1999, Tedaldi et al., 2003, Bica et al., 2001). Further research is 
therefore critical.  
 
1.4.4 Management of co-infected patients 
1.4.4.1 Anti-HCV Treatment 
The response rate to anti-HCV therapy is lower in HIV co-infected patients (Rockstroh and 
Spengler, 2004, Sherman, 2004). It is hypothesized that the higher HCV viral loads and 
lower response rates may necessitate longer duration and/or higher doses of interferon α 
and ribavirin in co-infected patients (Fuster and Clotet, 2003, Gonzalez and Talal, 2003). 
The incidence of adverse events necessitating withdrawal of anti-HCV therapy is also 
higher in co-infected patients (Rockstroh and Spengler, 2004, Sherman, 2004). 
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There are also concerns about the safety and tolerability of interferon/ribavirin therapy in 
HIV co-infected patients, particularly those on HAART. Ribavirin at high doses may have 
a lymphotoxic effect and may lead to a decrease in absolute CD4+cell counts (Rockstroh 
and Spengler, 2004).  
 
Interferon α may also lead to a drop in white cell and absolute CD4+ cell counts due to its 
myelosuppressive effects (Thomas, 2002). Up to 80% of patients treated with interferon 
experience a drop in CD4+ cell counts (Maier and Wu, 2002). A drop in the CD4+ cell 
count may in turn increase the risk of developing opportunistic infections (Mohsen et al., 
2002), although other authors have disputed this on the basis that the CD4+cell percentage 
remains unaltered despite the drop in the absolute CD4+ cell count (Sulkowski and 
Thomas, 2003, Thomas, 2002). 
 
Cytopenias are an important concern in the treatment of co-infected patients. Neutropenia 
and anaemia due to interferon therapy are of particular concern in the 
immunocompromised patient (Sherman, 2004). Co-infected patients treated with ribavirin 
and AZT are also more prone to anemia (Maier and Wu, 2002, Rockstroh and Spengler, 
2004, Sulkowski and Thomas, 2003, Thomas, 2002). 
 
The incidence of side effects of anti-HCV therapy such as influenza-like symptoms, 
haematological abnormalities and neuropsychiatric disorders is higher in co-infected 
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patients. This necessitates dose reductions or treatment discontinuation (Rockstroh and 
Spengler, 2004). 
 
1.4.4.2 Anti-HIV Treatment 
CD4+ cell recovery following HAART may be impaired in co-infected patients (Dieterich, 
2004, Fuster and Clotet, 2003, Gonzalez and Talal, 2003, Greub et al., 2000). Conversely, 
others have not demonstrated this effect, and have shown that response to HAART and risk 
of disease progression and death is not influenced by HCV co-infection (Sulkowski et al., 
2002, Rancinan et al., 2002). 
 
Initiation of HAART may lead to transient increases in HCV viral load and liver enzymes 
(Dieterich, 2004, Mohsen et al., 2002, Winnock et al., 2004). In patients with low CD4+ 
cell counts, the increased HCV RNA levels may persist for up to 48 months following 
initiation of HAART. This paradoxical increase in HCV viral loads may reflect increased 
replication in an extra-hepatic reservoir or decreased immune-mediated clearance of HCV 
(Sherman, 2004). On the other hand, immune reconstitution following 12 months of 
HAART is associated with decreases in HCV viral load (Rockstroh and Spengler, 2004), 
and even spontaneous clearance (Winnock et al., 2004). 
 
HAART seems to modify the natural history of HCV infection. Patients on protease 
inhibitors, for example, have decreased intrahepatic viral loads (Winnock et al., 2004), 
 45
lower rates of fibrosis (Fuster and Clotet, 2003, Khalili and Behm, 2002, Mohsen et al., 
2002, Thomas, 2002), improved outcome of HCV disease and decreased liver related 
mortality (Rockstroh and Spengler, 2004). These benefits of HAART may outweigh the 
associated risk of hepatotoxicity.  
 
1.4.4.3 Hepatotoxicity 
HCV infection is a risk factor for HAART induced hepatotoxicity (Maier and Wu, 2002, 
Mohsen et al., 2002, Sherman, 2004, Sulkowski and Thomas, 2003, Thomas, 2002). 
HAART-related hepatotoxicity is 3 to 4 times more common in HCV infected patients 
(Fuster and Clotet, 2003). This may lead to discontinuation of ARVs (Dieterich, 2004). 
Nevirapine and ritonavir, in particular, are associated with an increased risk of 
hepatotoxicity, and didanosine and stavudine with hepatic steatosis, in co-infected patients. 
Hepatic steatosis is associated with an increased risk for fibrosis and decreased response to 
interferon therapy (Rockstroh and Spengler, 2004). Co-infected patients who are on 
HAART therefore require closer monitoring of liver function particularly in the first few 
months after initiation of therapy (Bonacini and Puoti, 2000, Gonzalez and Talal, 2003, 
Khalili and Behm, 2002, Sulkowski and Thomas, 2003, Mohsen et al., 2002).  
 
The mechanisms of hepatotoxicity in co-infected patients include altered drug metabolism, 
HCV-specific immune reconstitution and mitochondrial dysfunction (Sulkowski and 
Thomas, 2003). HAART decreases HIV viral load and restores CD4+cell counts. This is 
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postulated to enhance the intra-hepatic immune response against HCV-infected 
hepatocytes, resulting in necroinflammation, hepatic decompensation and liver failure.  
 
Co-infected patients are less likely to be prescribed HAART due to hepatic complications, 
poorer compliance or substance abuse (Falusi et al., 2003, Gonzalez and Talal, 2003). 
 
1.4.4.4 Drug Interactions 
Therapy of the co-infected patients is complex and challenging due to drug-drug 
interactions and additive toxicities. Ribavirin may inhibit mitochondrial DNA polymerase. 
There are therefore concerns about adverse effects of ribavirin, including the risk of lactic 
acidosis, in the context of mitochondrial toxicity associated with antiretroviral therapy 
(Bonacini and Puoti, 2000, Khalili and Behm, 2002, Mohsen et al., 2002). The concurrent 
use of didanosine and ribavirin, for example, is contraindicated due to the increased risk of 
mitochondrial toxicity and associated pancreatitis, liver failure and lactic acidosis 
(Rockstroh and Spengler, 2004, Sherman, 2004). Furthermore, ribavirin, a nucleoside 
analogue, increases the intracellular availability of phosphate, thereby facilitating the 
conversion of didanosine to its active triphosphorylated form. This leads to increased drug 
levels and exacerbation of toxicities (Sherman, 2004, Thomas, 2002). Conversely, ribavirin 
decreases the efficacy of zidovudine and stavudine by interfering with their intracellular 
phosphorylation (Bonacini and Puoti, 2000, Khalili and Behm, 2002, Maier and Wu, 2002, 
Rockstroh and Spengler, 2004, Sulkowski and Thomas, 2003, Thomas, 2002, Gonzalez 
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and Talal, 2003). The adverse effects of anti-HCV therapy may impact on the adherence to 
HAART (Bonacini and Puoti, 2000).  
 
1.4.4.5 Antiretroviral therapy as a confounding factor in co-infection studies 
HAART significantly reduces mortality and morbidity in patients with HIV (Thomas, 
2002, Mohsen et al., 2002, Khalili and Behm, 2002, Rockstroh and Spengler, 2004, 
Sulkowski and Thomas, 2003, Bica et al., 2001, Martinez-Sierra et al., 2003, Klein et al., 
2003, Law et al., 2004). HCV-HIV co-infected patients, however, may not derive benefits 
from HAART (Klein et al., 2003) because they are less likely to receive or initiate 
HAART (due to concerns regarding hepato-toxicity (Fuster and Clotet, 2003, Anderson et 
al., 2004, Dorrucci et al., 2004, Rockstroh et al., 2005, Rossi et al., 2002, Sulkowski et al., 
2002) or the use of intravenous drugs (Sulkowski et al., 2002)). Furthermore, tolerance to 
ARVs may be reduced because HAART-associated liver injury and toxicity is worsened 
by HCV infection (Braitstein et al., 2005, Khalili and Behm, 2002). This leads to 
decreased adherence (Falusi et al., 2003) or earlier discontinuation of HAART in HCV 
positive patients (Rancinan et al., 2002, Bica et al., 2001, Klein et al., 2003). Co-infected 
patients may also have poorer compliance to HAART, specifically if they abuse 
intravenous drugs (Dorrucci et al., 2004, Klein et al., 2003). Antiretroviral therapy 
therefore confounds outcomes analysis because HAART affects survival and outcome 




Furthermore, HAART affects HCV-HIV co-infected and HIV mono-infected patients 
differently. HAART causes a transient increase in HCV viral load (Bonacini and Puoti, 
2000, Dieterich, 2004, Sherman, 2004, Staples et al., 1999), increases serum transaminase 
levels (Sherman, 2004, Staples et al., 1999, Graham et al., 2001), exacerbates hepatic 
necro-inflammation (Bonacini and Puoti, 2000, Mohsen et al., 2002, Rosenthal et al., 
2003) accelerates the progression of liver disease (Rosenthal et al., 2003) and precipitates 
liver failure (Bonacini and Puoti, 2000) and hepatic decompensation (Graham et al., 2001) 
in co-infected patients. HCV infection is a risk factor for HAART-related hepatotoxicity 
(Fuster and Clotet, 2003, Khalili and Behm, 2002, Maier and Wu, 2002, Mohsen et al., 
2002, Rockstroh and Spengler, 2004, Sherman, 2004, Sulkowski and Thomas, 2003, 
Winnock et al., 2004, Bica et al., 2001, Rosenthal et al., 2003, Law et al., 2004) and lipo-
atrophy (Mohsen et al., 2002). Indinavir can cause severe hyperbilirubinaemia (Maier and 
Wu, 2002, Mohsen et al., 2002), while the risk of hepatic steatosis in patients using the “d- 
nucleosides” (didanosine and stavudine) (Rockstroh and Spengler, 2004) is increased in 
co-infected patients. On the other hand, protease inhibitors may have a protective effect in 
HCV-related liver disease by decreasing fibrosis rates (Rosenthal et al., 2003, Fuster and 
Clotet, 2003, Mohsen et al., 2002, Rockstroh and Spengler, 2004, Graham et al., 2001, 
Marine-Barjoan et al., 2004, Martinez-Sierra et al., 2003). 
 
 
Anti-retroviral therapy is therefore a confounding factor in HIV-HCV co-infection studies 
(Braitstein et al., 2005, Rosenthal et al., 2003, Salmon-Ceron et al., 2005, Staples et al., 
1999, Tedaldi et al., 2003, Monga et al., 2001, Rockstroh, 2006, Rockstroh et al., 2005, 
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Lincoln et al., 2003) because its use and effects are different in HIV mono-infected and 





HIV infected individuals should be screened for anti-HCV antibodies and Hepatitis B 
surface antigen, using EIAs, when clinically indicated (Gonzalez and Talal, 2003, Mohsen 
et al., 2002, Sulkowski and Thomas, 2003). HCV RNA PCR should be used to confirm 
HCV infection (Thomas, 2002). Co-infected patients should have their liver function 
(aminotransferases, albumin and bilirubin) and prothrombin time/INR and platelet counts 
assessed. A liver biopsy and HCV RNA levels should also be performed in patients being 
considered for treatment (Thomas, 2002). 
 
Co-infected patients should be immunized against hepatitis A and B and be strongly 
advised to completely abstain from alcohol. (Bonacini and Puoti, 2000, Mohsen et al., 
2002, Sulkowski and Thomas, 2003, Thomas, 2002) 
 
HAART is highly recommended in co-infected patients because it lowers fibrosis rates 
(Fuster and Clotet, 2003). Concerns over hepatotoxicity should not be a reason to withhold 
HAART in co-infected patients (Thomas, 2002). 
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Pegylated Interferon-α and ribavirin in combination lowers the risk of hepatocellular 
carcinoma and liver failure and may lead to viral clearance. This combination is considered 
the optimal form of therapy and should therefore be considered in co-infected patients 
(Sulkowski and Thomas, 2003). 
 
1.5 HCV and Hepatitis B Virus (HBV) 
The clinical features of acute and chronic hepatitis B infection may be indistinguishable 
from those of Hepatitis C infection (Fields et al., 2001). HCV and HBV may also have 
similar extra-hepatic manifestations (Fields et al., 2001, Han, 2004). Both HBV and HCV 
are associated with increased liver mortality in HIV-infected patients (Bonacini et al., 
2004, Law et al., 2004). Patients who have infection with both HBV and HCV have a 
poorer prognosis than those infected with either one of the viruses alone (Brook, 2006, 
Gaeta et al., 2006). HBV infection may therefore be a powerful confounding factor in 
studies investigating HCV clinical outcomes and interactions, particularly in regions where 
HIV, HBV and HCV are endemic. 
 
Chronic Hepatitis B virus infection is endemic in Sub-Saharan Africa. The hepatitis B 
surface antigen carrier rate in South Africa averages 9%, but varies widely between 1 – 
17% in various cohorts (Firnhaber et al., 2008, Sanne et al., 2005, Hoffmann et al., 2007, 
Kotzee et al., 2006, Kew, 2008, Burnett et al., 2005). The prevalence of hepatitis B 
infection in HIV infected individuals may furthermore be increased by up to 2 fold  in Sub-
Saharan Africa and by up to 10-fold in certain risk groups (Alter, 2006, Burnett et al., 
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2005). There may also be an epidemiological association between HBV and HCV infection 























1. To determine the prevalence of HCV in this study population 
2. To determine the difference, if any, in the prevalence of HCV in HIV 
positive and negative subjects 







2 CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 Study Design and Rationale 
A representative sampling frame was required in order to achieve the first objective of the 
study, which was to determine the prevalence of HCV in this region. The study was 
therefore conducted in a centralised virology laboratory which received the majority of 
specimens for viral assays in the region. The majority of the 198 hospitals and 428 clinics 
in KwaZulu-Natal in 2003 were public health facilities. Only 10 - 11% of the population 
had medical aid coverage and the rest relied primarily on state health-care services 
(Lehohla, 2006). Approximately 90% of the population was therefore served by the 
Provincial Laboratory Services, which included the Virology laboratory in which this study 
was based. The population served by the laboratory was therefore a representative 
sampling frame of the population of KwaZulu-Natal. 
 
It was also essential to ensure that the sentinel sites selected were representative of this 
sampling frame. Of the 9.4 million people in the Province of KwaZulu-Natal, aproximately 
46% live in urban areas, of which the majority (over 3 000 000) reside in the Ethekwini 
District, in which our sentinel sites are located (Lehohla, 2006). The selected sentinel sites 
are referral hospitals within the region and receive a representative spectrum of patients 
from all regions of the province. The samples were from inpatients and outpatients and 
included medical, surgical, obstetric and gynaecological patients. The sentinel sites include 
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a flagship tertiary and quaternary hospital and several regional and district hospitals (Table 























A flagship tertiary and quaternary hospital providing patient care to all 
persons in KwaZulu-Natal and part of the Eastern Cape. 
(http://www.ialch.co.za) 
King Edward King Edward VIII Hospital is the second largest hospital in South Africa 
providing a tertiary service for the entire province of KZN and parts of 





MGMH District Hospital serves the population of Phoenix, Inanda, 
Amaoti, Mt Edgecombe and Duffs Road and also provides Regional 
services in Internal Medicine, Obstetrics and Gynaecology, Neonatology 
and Paediatrics to the population of Kwa-Mashu, Tongaat, Verulam and 
Ndwedwe. 
(http://www.kznhealth.gov.za/mahatma/history.htm) 
Addington Addington is a district and regional hospital, situated on South Beach, 
Durban. There are 16 clinics in Addington's catchment area. 
http://www.kznhealth.gov.za/addingtonhospital.htm
RK Khan RK Khan is a regional and district hospital located in Chatsworth, a 
suburb in the eThekwini health district. RK Khan hospital serves the 
population of Chatsworth and surrounding areas. It is also a referral 















(Provided by Geographic Information Systems (GIS), KwaZulu-Natal Department of 





In order to achieve the second and third objectives of this study, which entailed studying 
the effects of HIV-HCV co-infection, it was necessary to select a population with a high 
prevalence of HIV, but one in which confounding factors such as the use of anti-retroviral 
drugs and intravenous drug abuse were absent. There were several reasons which made this 
a unique population in which to achieve the study objectives. 
 
1. The prevalence of HIV in KwaZulu-Natal is among the highest in the world. In 
2005, 39.1% of women attending antenatal clinics in the public sector were HIV 
positive (Anonymous, 2006) .  
2. HIV is predominantly a sexually transmitted infection in this region (Buve et al., 
2002, Simon et al., 2006) and the use of intravenous drugs is rare (Parry et al., 
2005).  
3. The study population was naïve to antiretroviral therapy. During the study period, 
<1% of the number of HIV infected patients in the province were on antiretroviral 
treatment in the public sector (ASSA, 2005).  Moreover, the patients in this study 
could not have been on antiretroviral therapy since patients already on antiretroviral 
therapy would not have required an HIV test and would therefore not have fulfilled 
the inclusion and exclusion criteria for this study (see 2.7). 
 
In order to achieve the aims of this study it was necessary to conduct a HCV sero-
prevalence survey to obtain prevalence and demographic data. It was also necessary to 
carry out a retrospective cross-sectional chart review to compare the effect of HCV on 
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outcomes in HIV positive patients. It was deemed necessary to combine these strategies 
(by using a subset of patients from the sero-prevalence survey in the cross-sectional chart 
review) because this was a unique time point in the evolving HIV epidemic: 
 
1. With time large numbers of patients would be recruited into the Antiretroviral 
Rollout programme and commence antiretroviral therapy (DOH(SA), 2000, 
DOH(SA), 2003). As a result, the study of HIV-HCV co-infection in ARV-naïve 
patients would become more difficult and less representative 
2. With time, the Voluntary Testing and Counselling (VTC) programme would result 
in the  widespread availability of “rapid” point-of care HIV tests (DOH(SA), 2000, 
Ramkissoon et al., 2004).  Subsequently, the number of samples referred to the 
central virology service for formal HIV ELISAs would diminish and the sampling 
frame would no longer be representative. 
 
2.2 Overview of the Study Design  
This study was a HCV sero-prevalence survey conducted on all samples submitted for 
routine HIV testing from selected sentinel sites to a central laboratory. A subset of patients 
in the sero-prevalence survey was entered into a retrospective cross-sectional chart review 
in order to compare the effect of HCV on outcomes in HIV positive patients. 
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2.2.1 Seroprevalence Survey 
All specimens from subjects aged 18 years and older, submitted for routine HIV testing, 
from the selected sentinel sites to the Department of Virology Laboratory at Inkosi Albert 
Luthuli Central Hospital, during the 18 month period ended June 2005 were tested, 
additionally, for anti-HCV antibodies. Samples were selected sequentially. Repeat, 
unsuitable or inadequate samples were excluded. HIV and HCV sero-status and basic 
demographic data (age and gender) were collated on 1937 sequential samples.  
 
2.2.2 Retrospective Chart Review 
Morbidity and mortality data was collected on a randomly selected subset of patients 
within the sero-prevalence survey.  50 HIV-HCV co-infected patients and 150 HIV-
positive, HCV-negative patients were selected for this purpose. Hepatitis B Virus (HBV) 
surface antigen ELISA was performed in this subset of patients. 







Figure 6 Flow Chart Summarising Study Methodology 
 
Sample submitted from sentinel site (see 2.3.2) to virology 
laboratory (see 2.3.1) for routine HIV test (n = 25077) 
 
Routine HIV results and 
demographic data obtained from 
laboratory database (See 2.11.3) 
5
HCV ELISA (see 2.8.2.1) performed 
on anonymised (See 2.11.3) residual 
serum (see 2.8.1) (n = 2000) 
Equivocal HIV and HCV 














HIV and HCV results and basic demographic data collated and analysed  
(See 2.10) for the SEROPREVALENCE SURVEY (See 2.2.1) (n = 1937) HB











Samples selected for study as per 
criteria (see 2.7) (n = 2000) Sag ELISA performed on available residual 
sera (See 2.8.2.2) (n = 150) 
CV positive 





 (n = 18) 
(See 2.9) 
150 HIV Positive-HCV Negative 
patients selected randomly 
(See 2.5 and 2.6) 
CTIVE CHART REVIEW (See 2.9 and 2.2.2)  
 positive-HCV positive and HIV positive-HCV negative 
atients compared (See 2.10) (n= 178) 
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2.3 Study Location 
2.3.1 The Laboratory 
This laboratory-based study was conducted in the Department of Virology at Inkosi Albert 
Luthuli Central Hospital, in Durban. This laboratory is the reference virology laboratory in 
the province of KwaZulu- Natal, South Africa. Specimens for HIV ELISA testing from 
patients presenting to public health facilities in the province are submitted primarily to this 
laboratory.  
 
2.3.2 The Sentinel Sites 
The sentinel sites are referral hospitals within the region which receive a representative 
spectrum of patients from all regions of the province (Table 1 and Figure 5). The samples 
were from inpatients and outpatients and included medical, surgical, obstetric and 
gynaecological patients. All patients from the sentinel sites who required an HIV ELISA 
would have had a sample submitted to the Department of Virology Laboratory at Inkosi 
Albert Luthuli Central Hospital. 
 
2.4 Study Period 
The study was conducted during the 18 month period from January 2004 to June 2005. The 
study period was determined by the time taken to achieve the required sample number 
 (see 2.6).  
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2.5 Sampling Strategy 
Five sentinel sites were selected based on the human resources available to obtain and 
record good clinical notes. All specimens from the selected sentinel sites, submitted to the 
Virology Laboratory for routine HIV testing, were entered into the sero-prevalence study. 
Samples were selected sequentially. All samples fulfilling the inclusion criteria were 
selected. Only samples with exclusion criteria were excluded (See 2.7 for exclusion and 
inclusion criteria). 
 
After completion of sample collection, a subset of the patients from the sero-prevalence 
survey was entered into a retrospective chart review. This subset included 50 HIV-HCV 
co-infected patients and 150 HIV positive-HCV negative patients randomly selected from 
the 1937 patients used in the sero-prevalence survey. Randomisation was performed on all 
1937 study numbers, using random numbers generated without replacement by 
STATA™10 (StataCorp, College Station, Texas, USA).  
 
2.6 Statistical Plan and Sample Size Estimation 
The sample size required to estimate the prevalence of HCV was calculated according to a 
standard formula (Kirkwood et al., 2003):  
n > [π(1- π)]/e2 
where n = required sample number,  
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π = proportion,  
and e = required size of standard error 
 
Estimates of the prevalence of HCV in this region vary from 1 to 6 % (Abdool Karim and 
Tait, 1993, Lodenyo et al., 2000, Madhava et al., 2002, Soni et al., 1993). A sample size of 
≥ 1521 is required if the prevalence is 1% with a 95% confidence interval of 0.5 to 1.5 %, 
assuming a power of 90%. 
 
If the prevalence is 6%, a sample size of 2166 yields a 95% confidence interval of 5 to 7 % 
(power = 90%). Therefore, a sample size of 2166 was adequate for the most likely 
estimates.  
 
The sample size required to detect a difference in HCV prevalence between HIV positive 
and negative groups was calculated according to a standard formula (Kirkwood et al., 
2003): 
Sample size per group =  
[u[π1(1- π1) + π2(1- π2)]1/2  + v[π'(1- π')]1/2]2[ π2  - π1 ]-2
where 
π1 and π2 are the assumed proportions (0.01 and 0.02 respectively) and π' their mean. 
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u = 1.28 and v = 1.96, corresponding to a power of 90% and significance level 5%, 
respectively. 
 
Assuming a minimum HCV prevalence of 1.5% and assuming a difference of 1% between 
groups to be meaningful at the 5% significance level, the minimum sample size per group 
is 2095. A difference between the groups, of 1%, was selected, based on the observation 
that HCV prevalence varies by at least 1% between HIV positive and negative groups in 
numerous studies (Gonzalez and Talal, 2003, Khalili and Behm, 2002, Maier and Wu, 
2002, Mohsen et al., 2002, Rockstroh and Spengler, 2004, Sherman, 2004, Sulkowski and 
Thomas, 2003, Thomas, 2002, Winnock et al., 2004, Soriano et al., 1999, Armstrong et al., 
2006, Shepard et al., 2005). Assuming that 45% of HIV results are positive would require a 
minimum total sample size of 4656. A sample size of approximately 5000 seemed to be the 
most appropriate based on the lowest anticipated estimates of the HCV and HIV 
prevalence. Interim, 6-monthly analyses were planned to assess the accuracy of the initial 
assumed estimates. 
 
An accurate sample size could not be determined for the morbidity and mortality analysis 
because the data required for the assumptions of the sample size calculation were lacking 
and the number of variables that were to be analysed was large. This component of the 
study was regarded as hypothesis-generating rather than hypothesis-testing. The sample 
size was limited by practical considerations which included the following: 
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• The personnel at the medical registries of the respective hospitals had limited time 
and resources to find and retrieve patients’ charts 
• It was time consuming and laborious to extract the required information from 
patients’ charts. 
• The charts were made available to the investigators for a limited time period, after 
which they had to be returned to the medical registry 
 
Limiting the sample size to 200 charts allowed the study to be completed within the 
required time-frame with the available resources. A randomly selected subset of 50 HIV-
HCV positive patients and 150 HIV positive-HCV negatives patients were entered into the 
retrospective chart survey. A 3:1 ratio of HCV positive to negative patients was opted for 
in order to increase the statistical confidence of the study (Barker et al., 1997). 
 
At the 18 month interim analysis, 2000 samples had been collected and the prevalence of 
HCV and HIV was found to be 6.4% and 40% respectively. The number of samples 
collected at this point was therefore adequate for the purposes of the prevalence estimates 
(Objective 1). Furthermore, the actual prevalence of HCV exceeded the minimum 
prevalence required to detect a difference between HIV positive and negative subjects, 
according to our initial sample size calculations (Objective 2). Since the primary objectives 
of our study were already achieved with the number of samples collected at this point, we 
could not justify further sample collection. Sample collection was therefore stopped and 
the chart review and analysis was completed (Objective 3). 
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2.7 Exclusion and Inclusion Criteria 
 Inclusion Criteria 
1. All specimens from the selected sentinel sites (Inkosi Albert Luthuli Central Hospital, 
Mahatma Gandhi Memorial Hospital, RK Khan Hospital, King Edward VIII Hospital 
and Addington Hospital) submitted to the Virology Laboratory for routine HIV testing 
2. Subjects aged 18 years and older 
 
Exclusion Criteria: 
1. samples submitted for a repeat (confirmatory) HIV test on the same patient within the 
defined study period, or samples repeated from the same patient for any other reason 
2. samples of inadequate volume 
3. Samples unsuitable for ELISA testing as determined by the manufacturers guidelines 
e.g. haemolysed samples 
4. those samples that required residual serum to be stored for medico-legal or other 
reasons as per routine laboratory standard operating procedures e.g. samples taken 
from patients following sexual assault and rape or needle-stick injuries 
5. Patients who have been, or are, on antiretroviral therapy 
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2.8 Laboratory Methods 
2.8.1 Specimen Collection and Processing 
Residual serum from specimens that had been subjected to an HIV test, and which would 
have otherwise been discarded, was utilised. 
 
2.8.2 ELISA 
The residual serum was tested for anti-HCV IgG antibodies and Hepatitis B Surface 
antigen. 
2.8.2.1 HCV ELISA  
A commercially available 3rd generation ELISA (ABBOTT AxSYM® HCV v 3.0, Abbott 
Laboratories, Abbott Park, IL, USA) was utilised according to the manufacturer’s protocol. 
This is a microparticle enzyme immunoassay for the qualitative detection of anti-HCV 
antibodies in human serum or plasma. The assay uses proteins coated on a microparticle 
solid phase to capture antibodies against structural and nonstructural proteins of HCV. The 
bound analyte is detected by an antibody coupled to an enzyme. This enzyme acts on a 
substrate to produce a fluorescent signal. The fluorescent signal is proportional to the 
amount of analyte present in the initial sample. 
 
Several recombinant proteins are included in the assay. Collectively they contain 
sequences of putative core structural proteins and nonstructural proteins NS3, NS4 and 
NS5 chimerically bound to superoxide dismutase (SOD) 
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The kit contains positive and negative controls and a calibrator for quality control 
purposes. The specificity and sensitivity of the assay are stated to be 99.84% and 100%, 
respectively (Package insert - ABBOTT AxSYM® HCV v 3.0, Abbott Laboratories, 
Abbott Park, IL, USA). 
 
2.8.2.2 HBV Surface Antigen ELISA  
The Cobas® HBsAg II and Roche Modular Analytics E170 were used for the qualitative 
determination of hepatitis B Surface Antigen in serum (Roche Diagnostics GmbH, 
Mannheim). This is an electrochemiluminescence immunoassay (ECLIA) based on the 
sandwich principle. Biotinylated anti-HBsAg antibodies and anti-HBsAg antibodies 
labeled with a ruthenium complex are mixed with the sample to form a sandwich complex. 
This complex binds to a streptavidin-coated microparticle via the interaction of 
streptavidin with biotin. This complex is magnetically captured onto the surface of an 
electrode. Unbound substances are removed. A voltage applied across the electrode 
induces a chemiluminescent signal which is measured by a photomultiplier. The software 
automatically determines the result by comparing this signal to calibrated signal-cutoff 
values. 
 
The kit contains controls and a calibrator for quality control purposes. The specificity and 
sensitivity of the assay are stated to be 100% (Package insert: Cobas® HBsAg II, Roche 
Diagnostics GmbH, Mannheim). 
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2.8.2.3 Quality Control Procedures 
The kits contain negative and positive controls. Routine maintenance and calibration is 
performed on the equipment as per manufacturers’ recommendations. The laboratory uses 
the United Kingdom National External Quality Assessment Service (NEQAS) to ensure 
quality of serology results (NEQAS). 
 
2.9 Data Collection Method: Clinical records 
A morbidity and mortality study was performed on a subset of patients within the 
seroprevalence study.  50 HIV-HCV co-infected and 150 HIV-positive, HCV-negative 
patients were randomly selected for this purpose. 178 charts were reviewed systematically. 
The remaining 22 patients (4 co-infected and 18 from the HIV positive-HCV negative 
subset) were excluded from the analysis because their charts were missing or contained 
inadequate data. The difference in the number of missing charts between the two groups 
was not statistically significant (p = 0.4). 
 
The visit at which the patient had the HIV test (that was sent to the Virology laboratory) 
was the time point of analysis of the retrospective chart review. The patient’s morbidity 
and mortality status at this visit was assessed.  The patients were not followed up, and 
events beyond this visit were not included in the study. A standardized form was used to 
record the clinical and laboratory data available at this visit (see 2.9 ). Data was extracted 
from the patients’ hospital charts by the investigators who were blinded to the HCV status 
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of the patient. Where there was more than one measurement for a particular variable, the 
earliest (i.e. baseline) reading was taken. The WHO (WHO, 2006) (See Appendix B), CDC 
(Castro et al., 1992) (See Appendix C), and Karnofsky (O'Dell et al., 1995) (See Appendix 
D) scores were inferred by the investigators using the available clinical information. The 
diagnosis of liver failure, cirrhosis and chronic liver disease, were similarly inferred by the 
investigators using the criteria listed in Appendix E (Braunwald et al., 2001). Particular 
note was made of recreational drug use, and risk factors for transmission such as blood 
transfusion, tattoos and scarification. If the patient died during the visit, the cause of death 
was ascertained from the death certificate.   
 
The Clinical Record Form was used to enable standardized collection of data (see 
Appendix A) 
 
2.10 Statistical Techniques and Analysis 
The sero-prevalence of HCV, together with 95% confidence intervals, was determined in 
the HIV positive and negative groups. The HCV sero-positivity in the HIV infected and 
uninfected groups were compared using the χ-squared test. A morbidity and mortality 
chart review was performed on randomly selected HIV-HCV co-infected patients and 
randomly selected controls from the HIV-positive, HCV-negative group. The information 
was entered into a Clinical Record Form (see 2.9 and Appendix A) and thereafter collated 
and entered into Access® (MicroSoft Corporation). The data fields included clinical 
information, laboratory data and other investigations as recorded in the patients’ charts. 
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The data was exported to Excel® (MicroSoft Corporation) and then STATA™ 9 
(StataCorp, College Station, Texas, USA), where statistical analysis was performed. For 
categorical data, Chi-squared test was used when Cochran’s criterion was fulfilled and 
Fisher’s Exact tests, when it was not. Student’s t test was used for continuous variables. A 
normal distribution was assumed (Bland, 2000). 
 
2.11 Ethical Considerations 
2.11.1 Ethics Approval 
Ethics approval for the study protocol was obtained from the University of KwaZulu-Natal 
Bioethics Committee (Ref. E141/02). 
 
This was a laboratory-based study utilising residual sera for hepatitis C and B testing and 
clinical data obtained from the patients’ hospital records. There was no direct patient 
interaction or contact. No additional blood samples were taken. No tests other than those 
for Hepatitis C and Hepatitis B were performed for the purposes of this study. Laboratory 
test results, where available, were obtained from the patients’ clinical records. These tests 
were performed routinely by the patients’ care provider independently of the study. 
 
The study was designed on the basis that only samples submitted to the laboratory for 
routine HIV testing were to be selected. Patients would therefore already have had HIV 
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results prior to entry into the study. HIV testing was therefore not performed solely for 
purposes of this study. 
 
2.11.2 Consent 
Informed consent was not obtained for the non-routine tests since these were performed 
anonymously on sera that would have otherwise been discarded. Informed consent for the 
routine HIV test would have been obtained by the patient’s care-giver, in accordance with 
Department of Health policies and guidelines (Tshabalala-Msimang, 2003). Use of 
anonymised discarded samples is acceptable in minimal-risk research, where the risk of 
breaching confidentiality by attempting to obtain informed consent is greater than the risk 
of conducting the research in an anonymous unlinked manner. The ethical basis and design 
of this protocol are in keeping with Section 9 of the South African National Department of 
Health Guidelines for good practice in the conduct of clinical trials in human participants 
in South Africa (Rees et al., 2000).  
 
In respect of the retrospective chart review, Guideline Four of the International Ethical 
Guidelines for Biomedical Research Involving Human Subjects, prepared by the Council 
for International Organizations of Medical Sciences in collaboration with the World Health 
Organization, Geneva (2002) states the following: 
“…when the research design involves no more than minimal risk and a requirement of 
individual informed consent would make the conduct of the research impracticable (for 
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example, where the research involves only excerpting data from subjects' records), the 
ethical review committee may waive some or all of the elements of informed consent.” 
(CIOMS and WHO, 2002) 
 
2.11.3 Patient Confidentiality 
The protocol was designed in a linked, anonymous manner to protect the confidentiality of 
patients with respect to clinical data and HIV, HBV and HCV status. This was achieved by 
adhering strictly to the following procedures: 
 
1. The Principal Investigator identified samples fulfilling the study criteria. Original 
sample tubes are routinely labeled with a unique HOSPITAL NUMBER. The 
hospital number facilitates retrieval of the patients’ medical records.  A “master 
list” was created linking the hospital number to a unique, sequentially-generated, 
anonymous STUDY NUMBER. It is impossible to identify patients using the study 
number alone. This “master list” was available only to the Principal Investigator. 
The HIV result, generated for routine clinical purposes, was recorded by the 
Principal Investigator, per study number (the “HIV result list”). The “HIV result 
list” was anonymous since it did not contain the hospital number or any other 
patient identifiers. The original specimen was aliqouted into an anonymous vial 
bearing only the study number.  
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2. The anonymous vials, bearing only the unique study numbers, were received by the 
technologist. The “HIV result list”, with the HIV result per study number, but 
without any personal patient identifiers, was provided to the technologist. The 
technologist was not given the “master list” or the patients’ hospital number or any 
other personal identifiers. The technologist performing the test was therefore 
blinded to the identity and personal and clinical details of the patients. The 
technologist performed the HCV and HBV serology and recorded this result, 
together with the HIV result (from the “HIV result list”), against the anonymous 
study number. The technologist randomly selected 50 HCV positive- HIV positive 
study numbers and 150 HCV negative-HIV positive study numbers as per 
randomization method (See 2.5). The technologist listed these study numbers, in 
ascending order, but WITHOUT the HCV/HBV/HIV results (the “randomized 
study number list”). It was therefore impossible to deduce the HCV/HBV results 
from this list, since the list consisted of study numbers only and these could belong 
to either HCV positive or HCV negative specimens. This list was provided to the 
Principal Investigator. 
 
3. The Principal Investigator used the Master List to link the anonymous study 
number in the “randomized study number list”, to the hospital number, and 
provided a list of corresponding hospital numbers, but NOT study numbers, to the 
medical practitioner, for collection of clinical data. The medical practitioner was 
therefore blinded to the HCV/HBV status of the patients. The medical practitioner 
extracted the clinical data using the hospital numbers as patient identifiers. The data 
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was recorded in the Clinical Record Form (see Appendix A). This data was 
provided to the Principal Investigator. 
 
4. The Principal Investigator collated the data into a spreadsheet, in which the clinical 
data was arranged per hospital number. Patient names and other personal details or 
patient identifiers were not recorded on the spreadsheet. The Principal Investigator 
replaced the hospital number with the unique study number, using the Master List. 
The Master list was then destroyed. It was thereafter impossible to link the data in 
the spreadsheet to individual patients i.e. the spreadsheet was anonymous. 
 
5. The spreadsheet containing the anonymised clinical data, with no personal patient 
identifiers, was provided to the technologist who entered the HCV/HBV results per 
study number.  
 




2.11.4 Patient Impact 
A consequence of the design of this study was that the HCV and HBV results could not be 
made available to the patients even if this may have been desirable or even lifesaving          
(consider unlinked anonymous HIV surveillance as an analogy)  
“Unlinked anonymous testing without informed consent is only conducted in clinical 
settings in which a specimen of blood originally collected for other purposes, such as 
syphilis testing at antenatal clinics, is tested for HIV after all information that could 
identify the source of the blood is removed from the specimen. Thus, the test result may not 
be traced back to the patient nor may he or she be informed of the test results.” 
(WHO, 2001) 
 
The patient and care-provider still had access to his/her HIV results and routine care, 
which is not compromised by this study. The study did not interfere with or diminish the 
standard of care available to the patient. At the time that this study was conducted, 
treatment for hepatitis C infection was not routinely available in the study population. The 
research or surveillance purpose was separate from and did not intrude on the clinical 
function. 
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3 CHAPTER THREE: RESULTS 
3.1 Prevalence 
Table 2 shows the HIV and HCV results of 1937 samples entered into the sero-prevalence 
survey (of the 2000 samples screened, 63 had equivocal HIV and/or HCV ELISA results 
and were excluded from the analysis).  The prevalence of HCV in this study population 
was 6.4 % and that of HIV, 40.2%. There was a significantly higher prevalence of HCV 
among HIV infected patients as compared to HIV negative patients (13.4% vs. 1.73%)     
(p < 0.001, Odds Ratio (OR) 8.8, 95% confidence interval (CI) of the OR 5.4 - 14.3). 83.9 
% of individuals who were HCV positive were HIV positive as well. 
Table 2 Distribution of HCV among HIV Positive and Negative Individuals 
 HCV Negative HCV Positive Totals HCV Prevalence 
HIV Negative 1139 20 
 
1159 1.7% 
(0.98 – 2.48%) 
HIV Positive 674 104 
 
778 13.4% 
(11.0 – 15.8%) 
Total 1813 124 1937 6.4% 
(5.3 – 7.5%) 
HIV Prevalence 
(% and 95%CI) 
37.2% 
(35.0 – 39.4%) 
 
83.9% 
(77.4 – 90.4%) 
40.2% 
(38.8 – 42.4%) 
 
   
χ2  = 105, p < 0.001, n = 1937 
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3.2 Demographic Profile of HIV Positive and Negative Individuals 
Females were significantly more likely to be HIV positive than males (42.2 vs. 37.5 %, 
respectively, p = 0.043) (Table 3). The ratio of HIV seropositivity in females vs. males was 
1.12.  There was a significant difference between the mean age of HIV positive and 
negative patients (p < 0.0001) 
 
Table 3 Demographic Profile of HIV Positive and Negative Individuals 
Variable HIV Negative HIV Positive % 
positive 
Total Significance 
Total  1159 778 40.2% 1937  
Male 478 287 37.5% 765 
Female 656 478 42.2% 1134 
Unknown 25 13  38 
Female to 
Male ratio 






(41.7 – 43.5) 
35.0 
(34.3 – 35.8) 
  p < 0.0001b
 




3.3 Demographics Profile of HCV Positive and Negative individuals 
In comparison, the HCV seropositivity was 6.0 and 6.7 % in males and females, 
respectively (Table 4). The difference in HCV seropositivity between males and females 
did not reach statistical significance. The ratio of HCV seropositivity in females vs. males 
was 1.12. There was no statistically significant difference in the mean age between the 
HCV positive and HCV negative groups. 
 








Total  1813 124 6.4% 1937  
Male 719  46  6.0% 765  
Female 1058  76  6.7% 1134  
Unknown 36 2  38 
Female to 
Male ratio 






(39.0 - 40.3) 
38.7 
(36.4 - 41.0) 
 39.6 
(39.0 – 40.2) 
p = 0.476b
CI Confidence Interval 
aChi-squared test  bt-test with equal variances 
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3.4 Demographic Profile of patients selected for chart review 
Table 5 shows the baseline demographics in the subset of patients selected for the detailed 
chart review. There was no statistically significant difference in the female-to-male ratio or 
mean age between the HCV positive and HCV negative groups.  
 
Table 5 Demographic Profile of HCV Positive and Negative Individuals in the Subset 





% positive Total Significance 
Total  132  46  25.8% 178  
Male 46 14 23.3% 60 
Female 86 32 27.1% 118 
Female to 
Male ratio 






(33.2 - 36.5) 
36.3  
(33.7 - 38.8) 
 35.2 
(33.8 – 36.6) 
p = 0.366b
 
CI Confidence Interval 






3.5 Age-Gender Distribution 
Figure 7 shows the prevalence of HIV in men and women in different age groups. Figure 8 
shows the prevalence of HCV in men and women in different age groups. Both HIV and 





















Figure 8 Age Gender Distribution of HCV 
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3.6 Clinical Outcomes 
There was no difference in the proportion of patients admitted or length of hospital stay 
between HCV positive and negative patients (Table 6). Similarly, there was no difference 
in HIV disease progression, as measured by CDC classification and WHO staging, 
between HCV positive and negative patients. There was also no difference between these 
groups in terms of ambulation and Karnofsky score. HIV infected patients who were 
seropositive for HCV had significantly increased mortality (8 vs. 21 %) (p < 0.02, OR = 













Table 6 Clinical Outcomes in HCV Positive and Negative HIV-infected Individuals 
Variable HCV Negative HCV Positive Significance 
Ambulant 90/117 (76.9%) 26/35 (74.3%) P = 0.747a
Number Admitted to Hospital 94/125 (75.2%) 34/42 (81.0%) P = 0.446a







Number with AIDS-defining 
condition 
66/123 (54%) 26/42 (62%) P = 0.353a
Median WHO score 3 3  
Median Karnofsky score 70 70  
10/120 (8.3%) 
(3.4% - 13.3%) 
9/42 (21.4%) 
(9.0% - 33.8%) 
p < 0.05c 
 
Number of Deaths (Mortality 
rate) 
Odds Ratio = 3.0 95% CI of 
OR: 
1.12 – 8.00 
 
CI Confidence Interval, p-values in bold are significant at α = 0.05. 








3.7 Causes of Death 
The causes of death are shown in Table 7. The average age of death was 36 years in HIV 
mono-infected patients and 38 in co-infected patients. It is noted that the cause of death 
was an AIDS-defining condition or an AIDS-related condition in almost all patients. There 
were no patients whose death was attributed to an HCV-related condition such as end-stage 
liver disease or hepatocellular carcinoma. Renal failure or renal impairment appears in the 
death certificates of 5 patients (in bold italics). This finding, the statistical significance of 












































HCV STATUS  DIAGNOSES AT DEATH AGE 
1 N PTB 45 
2 N SAH, TCP, Kaposi’s, Histoplasmosis 32 
3 N Bronchopneumonia 50 
4 N PCP 29 
5 N Bronchopneumonia 48 
6 N Lymphoma(spine) 27 
7 N TB Meningitis/ miliary TB 16 
8 N Meningitis 24 
9 N Anemia CCF Renal Failure 36 
10 N GE, PTB 54 
11 P Renal Failure 29 
12 P HIVAN - renal failure 40 
13 P Toxoplasmosis meningitis 51 
14 P PTB, PCP, renal impairment 34 
15 P Pancytopenia, meningitis, pneumonia 33 
16 P TB Meningitis 29 
17 P Pneumococcol Meningitis 36 
18 P Renal failure, disseminated TB 57 
19 P Disseminated TB 35 
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3.8 Renal and electrolyte abnormalities 
Table 8 explores renal and electrolyte abnormalities in HCV negative and positive patients 
by analyzing the association between HCV sero-status and sodium, bicarbonate, urea and 
creatinine levels. There was a statistically significant association between HCV serostatus 
and abnormal urea and creatinine levels. A statistically significant association was also 



















Table 8 Renal and Electrolyte Abnormalities in HCV Positive and Negative HIV-
infected Individuals 
Variable HCV Negative HCV Positive Significance 
Renal Failure or Impairment 
Noted in Death Certificate 
1/10 (10%) 4/9 (44%) p = 0.141a
Mean Sodium (mmol/l) 
Reference Range: 132-146 
  135     
(134 - 136) 
131 
 (130 -133) 
p < 0.005b
Hyponatremia 30/100 (30%) 20/35 (57%) p < 0.005b
Hypernatremia 1/100 (1%) 0/35 (0%) p = 0.553c
Mean Potassium mmol/l 
Reference Range: 3.3 – 5.1 
4.01    
(3.85 -  4.18) 
4.37 
(3.97 -  4.78) 
p = 0.0538b
Hyperkalemia 5/99 (5%) 7/34 (21%) p < 0.05a
Mean Bicarbonate (mmol/l) 
Reference Range: 22 – 29 
22.03  
(20.94 - 23.12) 
19.05    
 (17.35 - 20.75) 
p < 0.01b
Low Bicarbonate 42/95 (44%) 23/33 (69.7%) p < 0.05c
Mean Urea (mmol/l) 
Reference Range: 1.7 - 8.3 
7.33     
(5.65 - 9.01) 
15.39    
 (8.28 - 22.50) 
p < 0.005b
High urea 24/99 (24%) 16/35 (46%) p < 0.05c
Mean Creatinine (µmol/l) 
Reference Range: 0 – 80 
145   
(103 - 186) 
252 
(126 - 378) 
p < 0.05b
High creatinine 51/99 (52%) 25/35 (71%) p < 0.05c
NOTE. CI Confidence Interval, Reference Ranges defined by the laboratory performing 
the test; p-values in bold are significant at α = 0.05; 




3.9 Liver Function 
Table 9 shows the relationship between HCV seropositivity and liver dysfunction. HIV 
positive patients who were HCV seropositive were twice as likely to have hepatomegaly as 
HIV mono-infected patients (p < 0.05). However, we found no statistically significant 
association between HCV seropositivity and jaundice, signs of chronic liver disease or 
liver failure. Patients with HCV infection did have slightly higher bilirubin levels, but this 
was not statistically significant. HCV seropositivity was associated with low albumin and 


















Table 9 Clinical and Laboratory Indicators of Liver Function in HCV Positive and 
Negative HIV-infected Individuals 
 




(11.3 – 26.7%) 
15/40 (37.5%) 
(22.5 - 52.5%) 
p< 0.05a
Liver Failure 0/100 (0%) 2/39 (5%) p = 0.077b
Chronic Liver Disease 0/100 (0%) 1/40 (2.5%) p = 0.286b
Jaundice 1/100 (1%) 2/40 (5%) p = 0.196b
Mean Albumin (g/l) 
Reference Range: 34-48 
24.3 
(22.1 – 26.4) 
   18.0 
(15.4 -  20.6) 
p < 0.005c
Hypoalbulinaemia 55/69 (80%) 22/22 (100) p < 0.05a
Mean Bilirubin (µmol/l) 
Reference Range: 0-17 
14.2 
(6.4 - 21.9 ) 
19.1 
(8.9 - 29.3 ) 
p = 0.51c
Hyperbilirubinaemia 9/69 (13%) 7/22 (32%) p = 0.057b
Mean (ALT) (U/l) 
Reference Range: 0-31 
29.2   
(23.4 -34.9 ) 
52.0 
(24.9  -  79.0 ) 
p < 0.05c
High ALT 20/69 (29%) 12/22 (55%) p < 0.05a
 
NOTE. CI Confidence interval, Reference Ranges defined by the laboratory performing 
the test; p-values in bold are significant at α = 0.05. 




3.10 Hepatitis B Virus  
Table 10 shows the differences between HBV positive and negative HIV infected patients 
in terms of several clinical and laboratory markers which were found to be significantly 
different in HCV negative and positive patients. None of the variables that were found to 
be significantly different in HCV negative and positive patients reached statistical 
















Table 10  Selected Clinical and Laboratory Variables in Hepatitis B surface antigen 
Positive and Negative HIV-infected Individuals 
 
NOTE. CI Confidence interval, Reference Ranges defined by the laboratory performing 
the test; at-test, bFisher’s Exact test, cChi-squared test 





Age (years) 35.7 33.4 p = 0.273a
Deaths; (mortality, %) 
(95% CI of mortality) 
16/124 ( 12.9 ) 
(7.0 -18.8 %) 
2/26 ( 7.69) 
(-2.5 – 17.9%) 
p = 0.457b
Hepatomegaly (%), (95% CI) 23/106 (21.7%) 
(13.9 – 29.5%) 
8/24 (33.3%) 
(14.5 – 52.2%) 
p = 0.227c
Serum sodium (mmol/l); (95% 
CI) 
Reference Range: 132-146 
134 
(133 – 135) 
133 
(130 – 136) 
p = 0.454a
Serum bicarbonate (mmol/l); 
(95% CI) 
Reference Range: 22-29 
22.0 
(20.8 – 23.1) 
20.2 
(18.8 – 21.7) 
p = 0.152a





(5.2 – 14.1) 
p = 0.925a
Serum creatinine (µmol/l); (95% 
CI) 
Reference Range: 0-80 
161 
(111 – 211) 
170 
(86 – 255) 
p = 0.859a
Serum albumin (g/l); (95% CI) 
Reference Range: 34-48 
23.7 
(21.5 – 25.8) 
19.6 
(15.4 – 23.8) 
p = 0.107a
Serum alanine transaminase 
(U/l);(95% CI)  
Reference Range: 0-31 
36.5 
(26.7 – 46.4) 
29.9 




3.11 Risk Factors 
There was no record of intravenous drug use in the clinical notes of any of the patients in 
this study. One patient, who was HIV positive but HCV antibody and HBV surface antigen 
negative, had evidence of traditional scarification. Nine patients had received a blood 
transfusion, 6 of whom had the study sample taken within 5 days of the transfusion, which 
would have been too early to detect hepatitis C antibodies or hepatitis B surface antigen 
(Fields et al., 2001). The remaining 3 patients (none of whom were HCV or HBV surface 

















4 CHAPTER FOUR: DISCUSSION 
 
Hepatitis C Virus (HCV) is a common infection in Human Immunodeficiency Virus (HIV) 
positive patients because of shared routes of transmission and common risk factors. HIV is 
known to affect the epidemiology, transmission, pathogenesis and natural history of HCV 
infection, primarily due to the immunosuppressive effects of HIV. Patients with co-
infection, for example, have higher HCV viral loads and are more likely to progress to 
chronic liver disease, cirrhosis, end-stage liver disease and hepatic failure, than HCV 
mono-infected patients. Treatment of both HIV and HCV is more complex in co-infected 
patients because of liver toxicity and drug interactions (Bonacini and Puoti, 2000, 
Gonzalez and Talal, 2003, Khalili and Behm, 2002, Mohsen et al., 2002, Rockstroh and 
Spengler, 2004, Sterling et al., 2003, Sulkowski and Thomas, 2003, Thomas, 2002, 
Winnock et al., 2004).  
 
On the other hand, the effect of HCV on HIV infection is controversial and less well 
understood. Some studies have shown that patients who have HCV have increased 
progression to an AIDS-defining condition and death and diminished CD4+cell responses 
while on potent anti-retrovirals (ARVs) (Greub et al., 2000). Conversely, other studies 
have not demonstrated these effects (Sulkowski et al., 2002, Staples et al., 1999). These 
studies are confounded by several factors including the use of intravenous drugs and 
variable anti-retroviral regimens. The effect of HCV on HIV disease progression in ARV- 
naïve subjects, in particular, has not been well studied.  
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There are no representative population-based studies investigating the prevalence of HCV 
in the province of KwaZulu-Natal in South Africa, where HIV is highly prevalent. The 
magnitude of the above issues is therefore unknown in this population. This laboratory-
based study was conducted in the Department of Virology Laboratory at Inkosi Albert 
Luthuli Central Hospital, in Durban in order to determine the prevalence of HCV and to 
elucidate the clinical and epidemiological interactions between HCV and HIV in this study 
population. 
 
There are several factors which make this a unique population and a unique time point in 
which to study HIV-HCV co-infection. Firstly, the prevalence of HIV in KwaZulu-Natal is 
among the highest in the world. In 2005, 39.1% of women attending antenatal clinics in the 
public sector were HIV positive (Anonymous, 2006) . The prevalence of HCV in this 
population, and hence the potential magnitude of the problems associated with HIV-HCV 
co-infection, has not been described. The high prevalence of HIV may also reveal effects 
of co-infection which may not be apparent in areas of lower HIV prevalence. The high 
prevalence of HIV has largely contributed to the low life expectancy of 43.3 years in this 
region (Lehohla, 2006). To our knowledge, there have been no population-based studies on 
HIV-HCV co-infection in regions with such high prevalence of HIV. Furthermore, the role 
of HCV in contributing to the low life expectancy has not been assessed.  
 
Secondly HIV is predominantly a sexually transmitted infection in this region (Buve et al., 
2002, Simon et al., 2006) and the use of intravenous drugs is rare (Parry et al., 2005). Most 
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co-infection studies have been conducted in populations where intravenous drug use is the 
predominant risk factor for transmission of both viruses. Intravenous drugs are a 
confounding factor in  morbidity and mortality studies and furthermore seroprevalence 
data in high risk cohorts cannot readily be extrapolated to the general population 
(Anderson et al., 2004, Braitstein et al., 2005, Greub et al., 2000, Dorrucci et al., 2004, 
Rosenthal et al., 2003, Tedaldi et al., 2003, Sterling et al., 2003, Carter, 2004, Jenny-
Avital, 2000, Klein et al., 2003, Rockstroh et al., 2005, Sulkowski et al., 2002). This is one 
of the first HIV-HCV co-infection studies where the effect of intravenous drug use is not a 
confounding factor.  
 
Thirdly, the study population was naïve to anti-retroviral therapy. Anti-retroviral therapy is 
a potential confounding factor in outcomes analysis of HIV-HCV co-infection (Braitstein 
et al., 2005, Rosenthal et al., 2003, Salmon-Ceron et al., 2005, Staples et al., 1999, Tedaldi 
et al., 2003, Monga et al., 2001, Rockstroh, 2006, Rockstroh et al., 2005, Lincoln et al., 
2003) because while its use significantly reduces mortality and morbidity in patients with 
HIV (Thomas, 2002, Mohsen et al., 2002, Khalili and Behm, 2002, Rockstroh and 
Spengler, 2004, Sulkowski and Thomas, 2003, Bica et al., 2001, Martinez-Sierra et al., 
2003, Klein et al., 2003, Law et al., 2004), HCV-HIV co-infected patients may not derive 
such benefits (Klein et al., 2003) because they are less likely to initiate or remain on 
HAART (Fuster and Clotet, 2003, Anderson et al., 2004, Dorrucci et al., 2004, Rockstroh 
et al., 2005, Rossi et al., 2002, Sulkowski et al., 2002, Braitstein et al., 2005, Khalili and 
Behm, 2002, Falusi et al., 2003, Rancinan et al., 2002, Bica et al., 2001, Klein et al., 2003).  
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Furthermore, the risk of ARV-associated hepato-toxicity is greater in co-infected patients 
(Fuster and Clotet, 2003, Khalili and Behm, 2002, Maier and Wu, 2002, Mohsen et al., 
2002, Rockstroh and Spengler, 2004, Sherman, 2004, Sulkowski and Thomas, 2003, 
Winnock et al., 2004, Bica et al., 2001, Rosenthal et al., 2003, Law et al., 2004) and 
HAART exacerbates the severity and progression of liver disease in HIV-HCV co-
infection (Sherman, 2004, Staples et al., 1999, Graham et al., 2001, Bonacini and Puoti, 
2000, Mohsen et al., 2002, Rosenthal et al., 2003). Therefore, the utilisation, risks and 
benefits of HAART are different in HIV mono-infected and co-infected patients.  
 
 
The National Department of Health of South Africa initiated the rollout of anti-retroviral 
therapy in 2004 (DOH(SA), 2003). Between March 2004 and May 2005, only 12 007 
patients commenced anti-retroviral therapy in public health facilities in KwaZulu-Natal 
(KZN-DOH). Based on actuarial estimates, this represents <1% of the number of HIV 
infected patients in the province (ASSA, 2005).  Moreover, the patients in this study could 
not have been on anti-retroviral therapy since patients already on anti-retroviral therapy 
would not have required an HIV test and would therefore not have fulfilled the inclusion 
criteria for this study. It was essential to conduct the study at this unique time point, since 
with time large numbers of patients would be recruited into the Anti-retroviral Rollout 
programme and commence anti-retroviral therapy. As a result, the study of HIV-HCV co-
infection in ARV-naïve patients would become more difficult and less representative. 
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Finally, the existence of a centralised Virology service which received the majority of the 
specimens for viral assays in this region was a source of a representative sampling frame 
for this population. This laboratory serves approximately 90% of the population of the 
province, which consists of 9.4 million people (Lehohla, 2006). This was in a unique time-
point, prior to the widespread availability of “rapid” point-of care HIV tests. The 
Department of Health in South Africa was at this juncture implementing its Voluntary 
Testing and Counselling (VTC) programme in which easily accessible point-of-care rapid 
tests for the diagnosis of HIV were being prioritised (DOH(SA), 2000, Ramkissoon et al., 
2004).  Subsequently, the number of samples referred to the central laboratory for formal 
HIV ELISAs would diminish and be less representative as they were being replaced by the 
widespread use of rapid tests. 
 
At the time this study was conducted, HCV serology for clinical or surveillance purposes 
was not routinely available in the public sector. There was a paucity of data on the sero-
prevalence and clinical impact of HCV in this study population. By conducting a 
seroprevalence survey, large numbers of HCV-HIV co-infected samples could for the first 
time be identified. For these reasons, it was essential and informative not only to conduct 
the seroprevalence survey at this unique time point but also to combine this with a 
retrospective cross-sectional chart review based on clinical information anonymously 
linked to the HIV and HCV results.  
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This study has found the overall prevalence of hepatitis C sero-positivity to be 6.4% (95% 
CI 5.3 – 7.5%). This is more than double the estimated global prevalence of 3% (Winnock 
et al., 2004), and higher than previous estimates of HCV seropositivity in this province, of 
1.7% and 0.9% among urban and rural blacks, respectively (Abdool Karim and Tait, 1993). 
The prevalence of HCV in this study is, as expected, higher than that of most developed 
countries (Ray Kim, 2002, Shepard et al., 2005), and is slightly higher than that of previous 
estimates within Sub-Saharan Africa (5.3%) (Madhava et al., 2002). The geographical 
variation in HCV prevalence is well known and reflects the relative contribution of the risk 
factors to the epidemiology of HCV in different parts of the world. These risk factors are 
poorly defined in developing regions of the world (Ray Kim, 2002, Shepard et al., 2005).  
 
There are few representative population-based studies investigating the prevalence of HCV 
in South Africa. The average prevalence was found to be 23.5% in high risk cohorts  
(patients with liver disease and patients receiving multiple blood transfusions, blood 
products, dialysis and renal transplants) and < 1% in low-risk blood donors (Madhava et 
al., 2002, Soni et al., 1993, Tucker et al., 1997). HCV antibodies were found in 1% of 
AIDS patients admitted to the Chris Hani Baragwanath Hospital in Johannesburg 
(Lodenyo et al., 2000), in 1.8% of healthcare workers (Vardas et al., 2002) in a large, 
urban referral hospital and in 11% of HIV-positive patients on antiretroviral drugs who 
experienced hepatoxicity (Sanne et al., 2005). The prevalence in KwaZulu-Natal was 
found to be 1.7% and 0.9% among urban and rural blacks, respectively (Abdool Karim and 
Tait, 1993). .  
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Studies in high or low risk cohorts are non-representative and may either over-estimate or 
under-estimate the true prevalence of HCV. The findings in low risk blood bank cohorts 
(Madhava et al., 2002, Tucker et al., 1997, Soni et al., 1993), in healthcare workers 
(Vardas et al., 2002) and in HIV-positive patients experiencing hepato-toxicity (Sanne et 
al., 2005) cannot be extrapolated to the general population. The sample size in Lodenyo’s 
study was only 100 (Lodenyo et al., 2000). Studies performed in the early 1990’s before 
the development of new more sensitive tests for HCV may have under-estimated the true 
sero-prevalence. Furthermore, these estimates were made prior to the effects of the HIV 
pandemic and therefore do not reflect the effects of HIV on HCV epidemiology. Indeed, 
the prevalence of HCV in the HIV negative group of our study (1.7%) is remarkably 
similar to the estimates of the prevalence of HCV in the studies conducted in the early 
1990s (Abdool Karim and Tait, 1993, Soni et al., 1993), perhaps reflecting the role of the 
subsequent HIV pandemic in the dramatic increase of HCV seropositivity. This finding is 
evidence of the validity and representativeness of our sampling frame. Slight differences in 
the estimates may be explained by the increased sensitivity of ELISA techniques with 
advances in technology. Our study is therefore representative of the population that is 
affected by the HIV pandemic within this province and is furthermore the first to estimate 
hepatitis C prevalence outside a risk-defined population.  
 
This study has found a significantly higher prevalence of HCV among HIV infected 
patients as compared to HIV negative patients (13.4% vs. 1.73%). This is one of the first 
studies to investigate the epidemiology of HCV in HIV-infected individuals in Africa. The 
paucity of information on co-infection rates in developing countries has been noted by 
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several authors (Shepard et al., 2005, Madhava et al., 2002). The only other study 
investigating co-infection in South Africa found the prevalence of HCV among HIV 
positive patients to be low (1%) (Lodenyo et al., 2000). The sample size in Lodenyo’s 
study, however, was only 100, and the sample was non-representative. 
 
The prevalence of co-infection depends on the common risk factor and route of 
transmission (Sherman, 2004, Sulkowski and Thomas, 2003, Thomas, 2002, Winnock et 
al., 2004). The prevalence of co-infection in our study (13.4%) is comparable to the 
prevalence of co-infection in heterosexual cohorts in other parts of the world (14.3%) and 
much lower than the prevalence in hemophiliacs (60 – 90 %) or in individuals who have a 
history of intravenous drug use (50% - 95%) (Bonacini and Puoti, 2000, Dieterich, 2004, 
Fuster and Clotet, 2003, Gonzalez and Talal, 2003, Khalili and Behm, 2002, Maier and 
Wu, 2002, Rockstroh and Spengler, 2004, Sulkowski and Thomas, 2003, Thomas, 2002). 
This suggests that HCV is predominantly a sexually transmitted infection in this region. 
Furthermore, there were no other risk factors such as intravenous drug use, traditional 
scarification or blood transfusion that adequately explained the high prevalence of HCV in 
this population. There was no record of intravenous drug use in the clinical notes of any of 
the patients in this study. One patient had evidence of traditional scarification and nine 
patients had received a blood transfusion. The outcomes of the study were not influenced 
when these patients were analyzed separately. The Blood Transfusion Service routinely 
screens donor samples serologically for HIV, HCV and Hepatitis B (Madhava et al., 2002). 
It is therefore unlikely that any of these risk factors could explain the high seroprevalence 
of HCV in this study population. 
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In our study, females were more likely to be HIV seropositive than males (42.2 vs. 37.5%, 
p < 0.05, Odds Ratio: 1.12). Females were similarly more likely to be HCV seropositive 
than males (6.7 vs. 6.0%, Odds Ratio: 1.12), although this did not reach statistical 
significance. The ratio of female-to-male seropositivity for HIV was remarkably similar to 
that of HCV (both approximately 1.12). This is in contrast to the USA, where HCV 
prevalence is higher in men than women and probably reflects high risk drug-taking, which 
is a risk factor more common in men than women in that country (Armstrong et al., 2006). 
The distribution of risk factors in developing regions has not been well described, and the 
demographic profile of HCV seropositive patients has not been previously documented. 
HIV is more common in females due to biological reasons related to sexual transmissibility 
(Buve et al., 2002). Similar biological factors could explain the female to male ratio of 
HCV and HIV in our study.  
 
The prevalence of HIV in females and males peaks in the 25 - 29 and 30 - 34 age groups, 
respectively (Figure 7). A similar trend has been shown in other studies and reflects, 
among other factors, the tendency for young women to have older men as partners (Glynn 
et al., 2001, Buve et al., 2002).  The peak for HCV positive females and males are virtually 
identical to those of HIV (Figure 8). A possible explanation of this phenomenon is that 
HIV and HCV are associated because of common risk factors which define their age and 
gender distribution. Since HIV is a heterosexually transmitted disease in this population 
(Buve et al., 2002), it seems likely that HCV shares the same route of transmission.  
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The rate of sexual transmission of HCV is generally regarded to be minimal (Wyld et al., 
1997) and the prevalence of HCV in sexual partners of HCV carriers is low (Bouvet, 2005, 
Fields et al., 2001, Heintges and Wands, 1997) but significantly higher than that of the 
general population (Wejstal, 1999). On the other hand, HCV seropositivity does correlate 
with the number of sexual partners, the presence of sexually transmitted infections, total 
number of sexual intercourse (Tahan et al., 2005), length of sexual exposure (Tong et al., 
1995) and employment in the sex industry (Sulkowski and Thomas, 2003, Fields et al., 
2001, Wejstal, 1999). Furthermore, the risk of HCV in female partners of HCV-infected 
men is reported to be increased 3.7 fold (Hisada et al., 2000). These conflicting findings 
make it difficult to assess the extent of the sexual transmission of HCV. Furthermore, 
studies on sexual transmission are confounded by factors such as the use of intravenous 
drugs, number of sexual partners and syphilis and HIV seropositivity (Sulkowski and 
Thomas, 2003, Winnock et al., 2004, Wejstal, 1999, Hughes and Mahy, 1998).  
 
This study provides evidence that HCV is sexually transmitted. Firstly, the high rates of 
HCV-HIV co-infection suggest that the risk factors responsible for HIV transmission 
favour HCV transmission as well. Secondly, both HIV and HCV have a female 
preponderance in this region. It is likely that the factor(s) responsible for the female 
preponderance of HIV apply to HCV as well. Thirdly, the age-gender distribution of HCV 
and HIV seropositivity are remarkably similar suggesting that HIV and HCV are 
associated because of common risk factors which define their age and gender distribution. 
Since HIV is predominantly a heterosexually transmitted infection in this region, a similar 
route of transmission for HCV would explain these phenomena. This contrasts with the 
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findings of other studies which regard sexual transmission of HCV to be relatively 
inefficient and not as important in the epidemiology of HCV as IVDU, blood transfusion 
and other parenteral routes (Wyld et al., 1997, Tor et al., 1990, Conry-Cantilena et al., 
1996, Gordon et al., 1992).  
 
The discrepancy between our study and those which regard the sexual transmission of 
HCV as inefficient, may be explained by the controversial postulate that the sexual 
transmission of HCV is enhanced in co-infected patients (Bonacini and Puoti, 2000, 
Gonzalez and Talal, 2003, Dieterich, 2004, Khalili and Behm, 2002, Maier and Wu, 2002, 
Mohsen et al., 2002, Winnock et al., 2004, Sulkowski and Thomas, 2003, Thomas, 2002, 
Eyster et al., 1991). It has been suggested that the sexual transmission of HCV is enhanced 
in co-infected patients due to higher HCV viral loads (Sulkowski and Thomas, 2003), in 
analogy to the documented increase in peri-natal transmission of HCV in co-infected 
mothers (Mohsen et al., 2002, Sherman, 2004, Thomas, 2002, Winnock et al., 2004). This 
is supported by the increased prevalence of anti-HCV antibodies in partners of co-infected 
patients (9.1%) compared to the partners of HCV mono-infected patients (as low as 2.6%) 
(Bonacini and Puoti, 2000, Gonzalez and Talal, 2003, Dieterich, 2004, Khalili and Behm, 
2002, Maier and Wu, 2002, Mohsen et al., 2002, Winnock et al., 2004). 
 
In contrast to the hypothesis of sexual transmission of HCV, the increased prevalence of 
HCV in HIV positive individuals in previous studies has been attributed to the use of 
intravenous drugs, which is regarded as the common risk factor in these individuals 
 106
(Sherman et al., 2002, Armstrong et al., 2006). In our study population, HIV is transmitted 
predominantly by the sexual route (Simon et al., 2006). The use of intravenous drugs in 
this population is rare as evidenced by epidemiological studies (Parry et al., 2005). 
Furthermore, there was no record of intravenous drug abuse in the clinical notes of any of 
the patients in this study. We therefore postulate that the common risk factor in this 
population is sexual transmission rather than intravenous drug use and that HCV, like HIV, 
is predominantly a sexually transmitted infection in this population. The increased sexual 
transmissibility of HCV in HIV positive individuals (Eyster et al., 1991, Filippini et al., 
2001) is the most likely explanation for the high prevalence of HCV among HIV positive 
patients in our study. This has important public health implications, because it suggests 
that HIV is fuelling the HCV epidemic and that HCV prevalence may rise to 
unprecedented levels.  
 
In this study, patients with HIV-HCV co-infection had a higher mortality than HIV mono-
infected patients (8.3 vs. 21 %). This difference was statistically significant. Increased 
mortality in co-infected patients has been demonstrated previously (Monga et al., 2001, 
Greub et al., 2000, Anderson et al., 2004, Braitstein et al., 2005, Klein et al., 2003). The 
increased risk of liver disease and hepato-toxicity, decreased use of anti-retroviral therapy, 
diminished response to HAART and the deleterious effects of intravenous drugs and 
alcohol have been suggested as possible reasons for the increased mortality in co-infected 
patients (Anderson et al., 2004, Bica et al., 2001, Braitstein et al., 2005, Greub et al., 2000, 
Monga et al., 2001, Rancinan et al., 2002, Rosenthal et al., 2003, Graham et al., 2001, 
Mohsen et al., 2002, Klein et al., 2003, Rockstroh et al., 2005, Rockstroh, 2006, Rossi et 
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al., 2002). An analysis of the causes of death (as documented in the death certificates) 
showed that the increase in mortality in this study was unrelated to HAART, intravenous 
drug use or alcohol and was due to an AIDS-defining condition rather than to liver disease. 
These findings are in contrast to other studies which suggest that the increased mortality in 
co-infected patients is due to liver disease and not advanced HIV disease (Monga et al., 
2001, Bica et al., 2001, Rosenthal et al., 2003). Furthermore, the study population was 
naïve to anti-retroviral therapy, and there was no record of intravenous drug use in the 
clinical notes of any of the patients in this study. This eliminates anti-retroviral therapy and 
intravenous drugs as contributory factors to the increased mortality, unlike most other co-
infection studies which fail to exclude these confounding factors. 
 
It may be argued that HCV sero-positivity is merely a marker for more advanced HIV 
disease and immuno-suppression and that there is no cause-effect relationship between 
HCV sero-positivity and mortality. However, we found no association between HCV 
serostatus and markers of HIV disease progression (World Health Organization(WHO) 
staging (WHO, 2006), Centers for Disease Control (CDC) classification (Castro et al., 
1992)) or between HCV serostatus and admission rates, length of hospital stay, Karnofsky 
Score (O'Dell et al., 1995) and whether the patient was ambulant or not. This suggests that 
the association between HCV and morbidity and mortality, as described in this study, is 
unlikely to be confounded by these factors.  Also, there was no significant difference in 
mean age between HCV positive and negative individuals (36.3, 95% CI 33.7-38.8 and 
34.8, 95% CI 33.2-36.5 years respectively, p = 0.366). This implies that HCV infection and 
outcomes are not merely associated by the accumulation of risk with age.  
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There was a non-significant trend towards mortality due to renal failure and a tendency for 
renal related problems in co-infected patients. There was a statistically significant 
association between HCV serostatus and abnormal urea and creatinine levels and between 
HCV seropositivity and hyponatremia, hyperkalemia and low bicarbonate levels. It is 
possible that the increased mortality associated with HCV sero-positivity may in part be 
explained by renal insufficiency and renal failure.  
 
The association between HCV and renal insufficiency was recently noted and the authors 
suggested chronic liver disease, intravenous drug use or other high risk behaviours as an 
explanation for the renal insufficiency in HCV positive patients (Franceschini et al., 2006). 
Renal disease has also been noted in HCV-HIV co-infected patients in another study, in 
which differences in the patients’ ages was offered as an explanation (Tedaldi et al., 2003). 
 
However, the patients in our study were naïve to anti-retroviral therapy and did not have 
evidence of intravenous drug use or stigmata of chronic liver disease. There was also no 
statistically significant difference in the mean age between HCV positive and HCV 
negative patients in this study. We therefore postulate that this unexpected association 
between co-infection and renal abnormalities is more likely to be due to other mechanisms.  
 
Several mechanisms may explain renal involvement in HCV-HIV co-infection (di 
Belgiojoso et al., 2002, Cheng et al., 1999).  Hepatorenal syndrome, mixed 
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cryoglobulinemia, fibrillary and immunoactoid glomerulonephritis and other 
glomerulopathies may be the mechanism of renal involvement in HCV infection.  HIV 
associated nephropathy (HIVAN), immune complex glomerulonephritis, and various other 
forms of glomerular diseases are the underlying mechanism in HIV infection.  These 
mechanisms may work in concert or even synergistically in co-infection. 
 
A previous paper from our center has reported the lack of association between HCV and 
membranoproliferative glomerulonephritis (Madala et al., 2003). However, their study 
specifically excluded HIV positive patients and therefore the findings cannot be 
extrapolated to HIV co-infected patients. Patients with HCV-HIV co-infection have more 
rapid progression of liver disease than HCV mono-infected patients (Graham et al., 2001, 
Mohsen et al., 2003). It is therefore not unlikely that the immunosuppressive effects of 
HIV may also influence the progression of HCV related renal disease. An alternate 
hypothesis is that a novel pathophysiological mechanism may exist. It is not known which 
of these mechanisms accounts for the renal involvement in HCV-HIV co-infected patients 
in our study.  
 
We noted that patients with HCV co-infection, when compared to HIV mono-infected 
patients, were twice as likely to have hepatomegaly but not other signs of chronic liver 
disease. None of the variables that were found to be significantly different in HCV 
negative and positive patients were significantly different between HBV negative and 
positive individuals, suggesting that HBV is not a confounding factor in this study. 
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Several limitations to the study design and methods are acknowledged and have been 
addressed. It may be argued that the difference in outcome between HCV positive and 
negative patients could have been better assessed within a longitudinal design rather than a 
cross-sectional study. The retrospective design of this study also makes the timing of 
infection difficult since it was not possible to tell which came first: HIV or HCV infection. 
The outcomes in HCV infection, however, would have required long follow-up periods in 
a longitudinal study design. A longitudinal study would also depend on the drop-out and 
mortality rate and HCV-negative patients remaining negative during follow-up (Tedaldi et 
al., 2003). Patients may also commence HAART at varying time points within the follow-
up period, making comparisons of outcomes difficult. This study was conducted at an 
opportune time, prior to the rollout of anti-retrovirals within this region. This allowed 
evaluation of outcomes without the confounding effects of anti-retroviral therapy. This 
study has also revealed certain outcomes, such as renal dysfunction, which may be the 
focus of future cohort studies.  
 
There may be sample bias, in that specimens selected from patients in whom an indication 
exists for an HIV test may have risk factors for HCV as well. This may have led to an 
overestimate of the prevalence of HCV by over-representing patients with these risk 
factors. On the other hand, not all samples that are received for HIV testing have a risk 
factor for HIV. HIV testing, for example, may be performed routinely preoperatively and 
in renal transplant and antenatal clinics, whether a risk factor exists for HIV or not. Also, 
samples for this study were from a central laboratory in the region that received all 
specimens for HIV testing from the sentinel study sites at the time the survey was 
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conducted. This laboratory is the reference virology laboratory in the province and 
provides diagnostic virology services to 90% of the population in this region. The results 
can therefore be more readily extrapolated to the general population served by the 
laboratory. This study provides an estimate that is far more accurate than previous studies 
which used high risk cohorts or low-risk blood donors and therefore either over-estimated 
or under-estimated the prevalence, respectively (Madhava et al., 2002, Soni et al., 1993).   
 
It may be argued that limiting the study to five sentinel sites may have also introduced 
sample bias. Limiting the study to the sentinel sites was based on the human resources 
available to obtain and record clinical notes. Limiting the data collection to two medically 
qualified practitioners reduced potential inter-observer bias. Limiting the number of sites to 
academic centres where good clinical records are maintained also reduces the bias that 
might be introduced due to variations in the quality of note-keeping. The selected sites are, 
nevertheless, referral hospitals within the region and receive a representative spectrum of 
patients from all regions of the province. The samples were from a wide range of inpatients 
and outpatients and included medical, surgical, obstetric and gynaecological patients.  
 
The HCV ELISA results were not confirmed by Polymerase Chain Reaction (PCR) or 
Recombinant Immunoblot Assay (RIBA). False negative HCV ELISAs may occur in the 
window period, in patients who are severely immuno-compromised or with mixed 
cryoglobulinemia (Richter, 2002, Colin et al., 2001, Pawlotsky, 1999, Pawlotsky, 2002, 
Patel et al., 2006). False positives also occur, even with third generation HCV ELISAs, 
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particularly in patients with low risk of HCV infection (Alter et al., 2003, Erensoy, 2001). 
False positives occur due to cross –reactivity (Pawlotsky, 1999) or nonspecific binding of 
serum immunoglobulins to contaminants in the ELISA kit (Erensoy, 2001). 
Hypergammaglobulinemia, liver disease, auto-immune disease and HIV infection may also 
cause false positive results (Colin et al., 2001). 
 
 Positive HCV ELISAs must be confirmed by a supplemental test such as RIBA or nucleic 
acid detection methods such as PCR (Erensoy, 2001, Alter et al., 2003, Patel et al., 2006). 
We feel, however, that although confirmatory testing is obligatory for the clinical diagnosis 
in individual patients, that the relatively small number of false positives do not 
significantly affect the interpretation of epidemiological studies.  The Abbott AxSym HCV 
version 3.0 has a specificity of 99.6% and sensitivity of 100% respectively (Package insert 
- ABBOTT AxSYM® HCV v 3.0, Abbott Laboratories, Abbott Park, IL, USA). If all false 
positives were excluded by a confirmatory test, the true prevalence would be 6.04%. This 
calculation is based on the stated sensitivity and specificity (see calculations in Appendix 
F). The 95% confidence interval of the estimated prevalence of HCV is 5.3 – 7.5%    
(Table 2). The true prevalence, measured by a test with no false positives, therefore falls 
within the confidence interval of the actual prevalence estimated without confirmatory 
testing. Confirming the false positives would therefore not have improved our prevalence 
estimates significantly. Approximately 2.8 - 5% of patients who are sero-negative will 
have detectable HCV RNA, and 5-10% of HCV seropositive patients will have 
undetectable HCV RNA. Therefore misclassification of HCV positive vs. HCV negative 
groups is minimal (Braitstein et al., 2005, Tedaldi et al., 2003). Numerous studies in co-
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infected patients have used seropositivity on a single ELISA (without PCR or RIBA) to 
define HCV infection (Anderson et al., 2004, Braitstein et al., 2005, Law et al., 2004, Gebo 
et al., 2003, Cacoub et al., 2001, Rosenthal et al., 2003, Tedaldi et al., 2003, Rockstroh et 
al., 2005, Lichterfeld et al., 2005, Staples et al., 1999, Bica et al., 2001).  
 
It was also considered that RIBA is not routinely performed in this laboratory and is costly 
and time-consuming. Furthermore, RIBA is known to yield indeterminate or even negative 
results and is particularly ineffective in resolving weakly positive EIAs (Erensoy, 2001, 
Richter, 2002). PCR could not be performed optimally in the context of this study design. 
The sensitivity of PCR is affected by sample collection, transport and storage (Damen et 
al., 1998, Halfon et al., 1996, Jose et al., 2003, Wang et al., 1992).  It has been 
recommended that serum be separated immediately upon clot formation, transported on 
ice, exposed to minimal freeze-thaw cycles (Halfon et al., 1996) and frozen immediately 
(Wang et al., 1992). These conditions could not be consistently maintained in this study 
since the samples were collected specifically for routine serology and not molecular 
analysis. The sample would usually be kept on the bench-top for prolonged periods, for 
example, prior to selection into the study. This is acceptable for serology, but not for PCR. 
We therefore did not consider PCR to be reliable in the context of this study design. PCR 
would have been useful in differentiating active from past infection (Erensoy, 2001, 
Richter, 2002). Approximately 15% of patients have acute HCV infection that is cleared 
without proceeding to chronicity (Marcellin, 1999, Fields et al., 2001). Although PCR 
would have identified such patients in our study, a prospective study using specimens 
collected specifically for that purpose would be a more appropriate means to achieve this.  
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Information on CD4+ cell counts and HIV viral loads were lacking, since these tests were 
not standard of care at the time of the study. Differences in CD4+ cell counts and HIV viral 
loads might explain differences in survival (Fields et al., 2001), and may be a confounding 
factor in this study . In the context of this study, however, an endpoint indicator of disease 
progression such as death or an AIDS defining condition is more useful than a 
measurement such as viral load and CD4+cell counts taken at single time point. Viral load 
and CD4+cell counts are inherently variable measurements, affected by intercurrent 
illnesses and other biological and technical factors (Bartlett and Gallant, 2005). While 
serial measurements are useful in monitoring of patients, measurement at a single time 
point in a cross-sectional study design is open to question. For these and practical reasons, 
we relied on  CDC (Castro et al., 1992), WHO (WHO, 2006) and Karnofsky (O'Dell et al., 
1995) scores to assess disease progression. These scores were inferred by the investigators 
using the available clinical information and were not recorded per se by the attending 
physician. Scoring depends on crude clinical information, which was readily available in 
the patients’ charts. Relying on the investigators to calculate the scores standardized the 
scoring and limited inter-individual variability in assigning these scores. 
 
The retrospective chart review is dependent on the quality and consistency of the clinical 
records. Records kept for clinical purposes may not necessarily fulfill the requirements of a 
clinical protocol. This study maintained a consistent quality of data by using a standardized 
clinical record form. This ensured that the necessary details were extracted from the 
clinical records as accurately and thoroughly as possible. The findings of hepatomegaly 
and increased ALT in HCV seropositive patients are well-known and expected features of 
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viral hepatitis (Monga et al., 2001) and therefore indicate that the study design was 
sufficiently sensitive to detect them. Caregivers may not have routinely enquired about or 
recorded scarification practices and the use of intravenous drugs in the clinical notes. 
Furthermore, since the latter may be (or may be perceived to be) a stigmatizing and illegal 
activity, responses may not reflect the true prevalence of intravenous drug use in this 
population. This limitation is inherent to the retrospective nature of this study and can only 
be addressed by conducting further research designed specifically to gather information 














This study has found a significantly higher prevalence of HCV among HIV infected 
patients as compared to HIV negative patients (13.4% vs. 1.73%) (p < 0.001, OR 8.8, 95% 
CI 5.4 -14.3). We postulate that HCV is sexually transmitted based on the observation that 
the age and gender distribution of HCV and HIV are similar. We also observed that HCV 
co-infection was associated with renal insufficiency and higher mortality (8.3 vs. 21 %, p < 
0.02, OR = 3, 95% CI: 1.12 to 8.00). There was a non-significant trend towards mortality 
due to renal failure. We noted that patients with HCV co-infection, when compared to HIV 
mono-infected patients, were twice as likely to have hepatomegaly but not other signs of 
chronic liver disease. These findings are not confounded by differences in age, stage of 
HIV disease or HBV surface antigen carrier status. 
 
The findings of this study have important implications for the diagnosis and management 
of co-infected patients. In view of the high prevalence of HCV in this population, 
screening of patients for HCV prior to commencing HAART or other potentially 
hepatotoxic agents should be considered in HIV positive patients. HCV should similarly be 
excluded in HIV infected patient who have elevated liver enzymes and abnormal renal 
function. Preventative measures against the sexual HIV transmission of HIV, such as 
barrier contraceptives, are necessary to prevent the transmission of HCV as well and 
should be reinforced, particularly in sero-discordant couples. There is a need for periodic 
surveillance to monitor trends in HCV seroprevalence (Hughes and Mahy, 1998). The  
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National HIV and Syphilis Antenatal seroprevalence surveys (Anonymous, 2006) provides 
a useful opportunity to conduct such studies.  
 
Finally, the surprising observation of renal abnormalities in co-infected patients is of great 
interest and has direct management implications. Our study demonstrates that renal 
abnormalities may exist in co-infected patients even in the absence of chronic liver disease 
or risk factors such as the use of intravenous drugs or antiretroviral therapy. Screening for 
HCV should be part of the routine workup of patients who are HIV positive who 
demonstrate renal insufficiency. Certain anti-retrovirals such as indinavir and tenofovir are 
nephrotoxic (Roling et al., 2006). This needs to be taken into consideration in the HCV-
HIV co-infected patient who may require closer monitoring of renal function when treated 
with these or other nephrotoxic drugs.  
 
Although HCV infection does occur in the absence of HIV, the natural history and 
prognosis of HCV infection is markedly different in HIV infected patients. The effect of 
co-infection on renal function, as demonstrated in this study, is clear evidence of this. 
Based on the results of this study we propose that HCV infection be regarded as a sexually 
transmitted, opportunistic infection (Graham et al., 2001) in HIV and that co-infection is a 
distinct entity from HIV and HCV mono-infection (Gonzalez and Talal, 2003, Winnock et 
al., 2004). This viewpoint necessitates a different approach to screening, diagnosis, 
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APPENDIX B: WHO Staging (WHO, 2006)  
Clinical stage I 
1. Asymptomatic  
2. Persistent generalized lymphadenopathy   
Performance scale 1: asymptomatic, normal activity 
Clinical stage II 
3. Weight loss, <10% of body weight  
4. Minor mucocutaneous manifestations (seborrheic dermatitis, prurigo, fungal 
nail infections, recurrent oral ulcerations, angular cheilitis)  
5. Herpes zoster within the last five years  
6. Recurrent upper respiratory tract infections (i.e. bacterial sinusitis)  







Clinical stage III 
7. Weight loss, >10% of body weight  
8. Unexplained chronic diarrhoea, >1 month  
9. Unexplained prolonged fever (intermittent or constant), >1 month  
10. Oral candidiasis (thrush)  
11. Oral hairy leukoplakia  
12. Pulmonary tuberculosis within the past year  
13. Severe bacterial infections (i.e. pneumonia, pyomyositis)  










Clinical stage IV 
14. HIV wasting syndrome, as defined by the Centers for Disease Control and 
Preventiona  
15. Pneumocystis carinii pneumonia  
16. Toxoplasmosis of the brain  
17. Cryptosporidiosis with diarrhoea  >1 month  
18. Cryptococcosis, extrapulmonary  
19. Cytomegalovirus disease of an organ other than liver, spleen or lymph nodes   
20. Herpes simplex virus infection, mucocutaneous >1 month, or visceral any 
duration  
21. Progressive multifocal leukoencephalopathy  
22. Any disseminated endemic mycosis (i.e. histoplasmosis, 
coccidioidomycosis)  
23. Candidiasis of the oesophagus, trachea, bronchi or lungs  
24. Atypical mycobacteriosis, disseminated  
25. Non-typhoid Salmonella septicaemia  
26. Extrapulmonary tuberculosis  
27. Lymphoma  
28. Kaposi’s sarcoma  
29. HIV encephalopathy, as defined by the Centers for Disease Control and 
Preventionb.  
 And/or performance scale 4: bedridden >50% of the day during the last month 
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Note: both definitive and presumptive diagnoses are acceptable. 
a. HIV wasting syndrome: weight loss of >10% of body weight, plus either 
unexplained chronic diarrhoea  
(>1 month) or chronic weakness and unexplained prolonged fever (>1 month). 
b. HIV encephalopathy: clinical findings of disabling cognitive and/or motor 
dysfunction interfering with activities of daily living, progressing over weeks to 
months, in the absence of a concurrent illness or condition other than HIV 











APPENDIX C: CDC Classification(Castro et al., 1992) 
The clinical categories of HIV infection are defined as follows: 
 Category A  
Category A consists of one or more of the conditions listed below in an adolescent or adult 
(greater than or equal to 13 years) with documented HIV infection. Conditions listed in 
Categories B and C must not have occurred.  
• Asymptomatic HIV infection  
• Persistent generalized lymphadenopathy  











Category B consists of symptomatic conditions in an HIV-infected adolescent or adult that 
are not included among conditions listed in clinical Category C and that meet at least one 
of the following criteria: a) the conditions are attributed to HIV infection or are indicative 
of a defect in cell-mediated immunity; or b) the conditions are considered by physicians to 
have a clinical course or to require management that is complicated by HIV infection. 
Examples of conditions in clinical Category B include, but are not limited to:  
• Bacillary angiomatosis  
• Candidiasis, oropharyngeal (thrush)  
• Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy  
• Cervical dysplasia (moderate or severe)/cervical carcinoma in situ  
• Constitutional symptoms, such as fever (38.5 C) or diarrhea lasting greater than 1 
month  
• Hairy leukoplakia, oral  
• Herpes zoster (shingles), involving at least two distinct episodes or more than one 
dermatome  
• Idiopathic thrombocytopenic purpura  
• Listeriosis  
• Pelvic inflammatory disease, particularly if complicated by tubo-ovarian abscess  
• Peripheral neuropathy  
For classification purposes, Category B conditions take precedence over those in Category 
A. For example, someone previously treated for oral or persistent vaginal candidiasis (and 
who has not developed a Category C disease) but who is now asymptomatic should be 
classified in clinical Category B.  
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Category C  
Category C includes the clinical conditions listed in the AIDS surveillance case definition. 
For classification purposes, once a Category C condition has occurred, the person will 
remain in Category C.  
Conditions included in the 1993 AIDS surveillance case definition  
• Candidiasis of bronchi, trachea, or lungs  
• Candidiasis, esophageal  
• Cervical cancer, invasive  
• Coccidioidomycosis, disseminated or extrapulmonary  
• Cryptococcosis, extrapulmonary  
• Cryptosporidiosis, chronic intestinal (greater than 1 month's duration)  
• Cytomegalovirus disease (other than liver, spleen, or nodes)  
• Cytomegalovirus retinitis (with loss of vision)  
• Encephalopathy, HIV-related  
• Herpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, 
pneumonitis, or esophagitis  
• Histoplasmosis, disseminated or extrapulmonary  
• Isosporiasis, chronic intestinal (greater than 1 month's duration)  
• Kaposi's sarcoma  
• Lymphoma, Burkitt's (or equivalent term)  
• Lymphoma, immunoblastic (or equivalent term)  
• Lymphoma, primary, of brain  
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• Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary  
• Mycobacterium tuberculosis, any site (pulmonary  or extrapulmonary)  
• Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary  
• Pneumocystis carinii pneumonia  
• Pneumonia, recurrent  
• Progressive multifocal leukoencephalopathy  
• Salmonella septicemia, recurrent  
• Toxoplasmosis of brain  
• Wasting syndrome due to HIV  
 









APPENDIX D: Karnofsky Score (O'Dell et al., 1995) 
100: Normal, no complaints or evidence of disease  
90: Able to perform normal activity; minor signs and symptoms of disease  
80: Able to perform normal activity with effort; some signs and symptoms of disease  
70: Cares for self, unable to perform normal activity or to do active work  
60: Requires occasional assistance but is able to care for most of own needs  
50: Requires considerable assistance and frequent medical care  
40: Requires special care and assistance; disabled  
30: Hospitalization indicated, although death not imminent; severely disabled  
20: Hospitalization necessary; active supportive treatment required, very sick  
10: Fatal processes progressing rapidly; moribund  






APPENDIX E: Signs and Symptoms of Liver Disease 
SIGNS AND SYMPTOMS OF LIVER FAILURE 
• Change in level of consciousness(confusion, coma or subtle perceptual 
abnormalities) 
• Other neurological manifestations(seizures, asterixis, hyper-reflexia) 
• Foetor hepaticus 
• bleeding tendencies 
• hypoglycemia 
 
SIGNS AND SYMPTOMS OF CIRRHOSIS 
• weight loss 
• chronic malaise 
• impotence, loss of libido, menstrual irregularities 
• oedema and/or ascites 
• distended abdominal veins 
• spider naevi and palmar erythema 
• gynaecomastia 
• testicular atrophy 
• hepatomegaly 
• splenomegaly 
• bleeding tendencies 
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• leuconychia 
• Dupuytren’s contracture 
• clubbing 
• abnormal pigmentation 
• jaundice 














APPENDIX F: The influence of test validity on prevalence estimates 
 
  GOLD STANDARD 
 + - TOTAL 
+ TP FP 124 
- 0 1813 1813 
TEST 
TOTAL   1937 
 
 
T = total, TP = true positives, TN = true negatives, FP = false positives 
FN = False Negatives, P = study positives  
By definition: 
True Prevalence = TP/T, Study Prevalence = P/T,  P = TP + FP 






In this study : 
Total = 1937, Study Positives = 124 ∴ Study Negatives = 1937 – 124 = 1813 
The kit package insert states the sensitivity and specificity of the Abbott AxSym HCV 
Version 3.0 to be 100% and 99.6%, respectively (Abbott Laboratories, Abbott Park, IL, 
USA) 
∴ Sensitivity = Se = [TP/(TP + FN)] ~ 1 ∴ FN = 0 and TN = 1813 
and specificity = Sp = [TN/(TN + FP)]  ~ 0.996 
 TN/(TN + FP) = 1813/(1813 + FP) = 0.996 
 1813 + FP = 1813/0.996 ~ 1820 
∴ FP = 1820 – 1813 = 7  
P = TP + FP    ∴ TP = 124 – 7 = 117 
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